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The role of EHD2 in triple-negative breast cancer tumorigenesis and progression
Timothy Alan Bielecki, Ph.D.
University of Nebraska, 2017

Supervisor: Hamid Band, M.D., Ph.D.
Triple-negative breast cancer (TNBC) comprises 10%-15% of all breast cancer cases, yet
is clinically challenging due to lack of targeted therapies which leads to higher mortality.
Molecular subtyping has identified the most aggressive subclasses of breast cancer to be
enriched in components of caveolae. While caveolae have been linked to many biological
processes, their precise role in TNBC is still poorly understood. EHD2, a member of the
C-terminal EPS15-Homology Domain-containing (EHD) protein family, has emerged as
a new regulator of caveolae dynamics and is essential to maintain a stable membrane
pool of caveolae. Studies in model cells demonstrate that caveolae facilitate repair of
plasma membrane injuries incurred under stressful conditions. Importantly, new
evidence suggests the invasiveness of tumor cells makes them vulnerable to plasma
membrane injuries and hence a robust repair mechanism is essential to protect injured
tumor cells from cell death.
EHD2 is found to be highly expressed within the basal myoepithelial layer
throughout mammary gland development. High EHD2 mRNA and protein expression
was observed in human TNBC cell lines and positively correlated with Caveolin-1 and
Caveolin-2 expression. Furthermore, by analyzing publicly available gene expression
databases, we found that high expression of EHD2 mRNA correlated with lower
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probability of survival in TNBC patients. This led us to hypothesize that EHD2 is a
marker and crucial regulator of tumorigenicity in TNBC. Using a cohort of 840 highlyannotated human breast cancer tissue samples, we discovered that high cytoplasmic
expression of EHD2 marked TNBC cases, and served as a robust prognostic indicator of
metastasis and lower patient survival. ShRNA-mediated knockdown of EHD2 in TNBC
cell lines reduced invasiveness, growth under anchorage-independent conditions, and
membrane repair ability in vitro. Using orthotopic implantation of human breast cancer
cell lines in mouse mammary gland, we observed a dramatic abrogation of tumor
growth and a reduction in metastasis of TNBC cell lines with EHD2 knockdown
compared to their controls. These findings indicate that EHD2 is a novel clinical
biomarker of poor prognosis in TNBC, and serves a novel role as a positive regulator of
caveolae-dependent protection of plasma membrane against injury, enabling
tumorigenicity and metastasis in TNBC. Our results support the potential of targeting
EHD2 to develop therapeutic approaches against TNBC.
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Chapter I: Introduction
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I.1 Introduction

Breast cancer affects more women than any other type of cancer and is the
second leading cause of cancer-related deaths among women (Figure 1.1) (Siegel, Miller,
and Jemal 2017). The disease is generally classified into three main molecular subtypes:
estrogen receptor (ER) and/or progesterone receptor (PR) enriched (or ER+/PR+), human
epidermal growth factor receptor (HER2) enriched (HER2+), and tumors without ER,
PR, or HER2 overexpression, typically referred to as triple-negative (Figure 1.2). This
classification system typically dictates the course of treatment for patients, and targeted
therapies have been developed to successfully treat tumors with elevated ER/PR, and
HER2 expression (Malhotra et al. 2010). Although triple-negative breast cancer (TNBC)
comprises only 10%-15% of all breast cancer cases, it is clinically challenging due to its
aggressiveness and current lack of targeted therapies (Marmé and Schneeweiss 2015).
TNBC itself is not a single disease. In fact, TNBC is comprised of 5 distinct subclasses
based on gene expression: Basal-like 1, Basal-like 2, luminal androgen receptor+,
mesenchymal, mesenchymal stem like, and immunomodulatory (Lehmann et al. 2011).
These efforts to further characterize TNBC have yielded a better understanding of this
heterogeneous disease and a large list of potential targets for therapy. One such target,
commonly expressed in the most aggressive subclasses, are cellular structures called
caveolae (Yadav, Chanana, and Jhamb 2015; Pinilla et al. 2006; Neve et al. 2006).
Caveolae, meaning “little caves” in Latin, are small (50-100 nm) plasma
membrane-associated invaginations involved in endocytosis, lipid regulation, signaling
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pathways, mechano-sensing, and membrane repair in many types of mammalian cells
(Parton and del Pozo 2013; Martinez-Outschoorn, Sotgia, and Lisanti 2015; Lucas
Pelkmans et al. 2004; L Pelkmans, Kartenbeck, and Helenius 2001; Okamoto et al. 1998;
Blouin et al. 2010). While these caveolae-mediated processes are well understood in
endothelial cells, adipocytes, and muscle cells, it’s unclear what roles caveolae play in
TNBC. Caveolin-1, an essential structural component and marker of caveolae, has both
oncogenic and tumor suppressor functions in many tumor types, including breast cancer
(Patani et al. 2012). Despite the considerable evidence that it serves as a tumor
suppressor in ER+/PR+ and HER2+ breast cancers (Nawaz et al. 1999; Mercier et al. 2009;
Thomas et al. 2010; Engelman et al. 1998), caveolin-1 functions mainly as a tumor
promoter in TNBC. Immuno-histochemical analysis of a 900-patient cohort revealed that
caveolin-1 protein expression is associated with TNBC (Elsheikh et al. 2008). In fact,
roughly 90% of metaplastic breast cancers, a type of TNBC that is highly aggressive and
difficult to treat, have been shown to express caveolin-1 (Savage et al. 2007).
Interestingly, the TNBC cell lines MDAMB231, Hs578t, and BT549 require caveolin-1 for
invadopodia formation and extracellular degradation in vitro (Yamaguchi et al. 2009).
Caveolin-1 and caveolin-2 are also highly expressed within the myoepithelial/basal layer
of the normal mammary duct (Figure 1.3) (Savage et al. 2008).
These findings suggest that caveolae are important for maintaining the
aggressiveness of TNBC. However, more recent studies indicate that the central function
of caveolae could be to protect the cell from plasma membrane stress and to repair
membrane damage (Figure 1.4). Stretching of the plasma membrane from the
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mechanical stress of osmotic shock causes caveolae to flatten and disassemble (Sinha et
al. 2011). Furthermore, work in muscle cells has shown that caveolae cluster and
regulate the repair of damaged regions of the plasma membrane (Corrotte et al. 2013).
While much of this work has been based on in vitro experiments, there is also
considerable evidence that the mechano-protective role of caveolae is physiologically
relevant. In mouse endothelial, caveolae flatten and disassemble in response to increased
membrane tension (Lo et al. 2015). The same study also found that vigorous muscle
activity leads to cell damage in live zebrafish embryos lacking caveolae (Lo et al. 2015).
Pharmacological stimulation of cardiac output increased mechanical stress, by
increasing blood flow, on endothelial cells, resulting in the flattening of endothelial
caveolae. Furthermore, depletion of caveolae made the endothelial cells more
susceptible to acute plasma membrane damage (Cheng et al. 2015). Caveolin-1 has also
been shown to be upregulated in TNBC cells subjected to fluid shear stress, indicating
that caveolae serve a mechano-protective role during breast cancer metastasis (H. Yang
et al. 2016).
Another ubiquitous component of caveolae and regulator of plasma membrane
repair is the Eps15 homology domain-containing 2 protein (EHD2). EHD2 is a member
of the EHD-containing protein family of ATPases that are endocytic trafficking
regulators similar to the dynamin family of GTPases (Figure 1.5) (George et al. 2007).
Our lab and others have found that EHD2 is also highly expressed in caveolae-rich
endothelial cells, adipocytes, and muscle cells (Figure 1.6)(Doherty et al. 2008; Sohn,
Brick, and Tuan 2016; Gudmundsson et al. 2010; Marg et al. 2012). In muscle, EHD2 and
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caveolae are required components of the plasma membrane repair process (Marg et al.
2012; Lo et al. 2015). EHD2 dimerizes and forms oligomeric rings around lipids (Figure
1.7) (Daumke et al. 2007). Contrary to the conventional endocytic trafficking role of the
EHD family, EHD2 is specifically localized to the necks of stable caveolae at the plasma
membrane and not involved in endocytosis or endosomal recycling (Figure 1.8) (Moren
et al. 2012; Stoeber et al. 2012; Ludwig et al. 2013). Although EHD2 is not required for
caveolae formation, EHD2 depletion increases caveolae mobility and caveolae budding,
resulting in more dynamic caveolae (Stoeber et al. 2012; Mohan et al. 2015; Shah et al.
2014).
Despite these recent advances in our understanding of how EHD2 regulates
caveolae stability and dynamics, there is little known about the involvement of EHD2 in
caveolae-mediated membrane repair and protection processes. In muscle cells, EHD2
binds to myoferlin and dysferlin, members of the ferlin family of proteins, which
facilitate myoblast fusion and membrane repair, respectively (Doherty et al. 2008; Posey
et al. 2011). The skeletal muscle membrane repair process has been even further
characterized more recently and shown to involved annexins and EHD2 was shown to
accumulate at the circumference of the repair patch (Figure 1.9) (Demonbreun et al.
2016). Ferlin-dependent membrane repair is a Ca2+-dependent process that intimately
involves caveolae (Cipta and Patel 2009). In endothelial cells, myoferlin binds to
caveolin-1 during membrane fusion and fission events, and loss of caveolin-1 impairs
membrane repair processes (Bernatchez et al. 2009). Recently, in vivo accelerated tumor
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growth of human and murine carcinomas was found to rely on functional myoferlindependent membrane repair processes (Leung et al. 2013).
Recently, EHD2 has been implicated as a tumor suppressor in breast cancer
(Yuhua Shi et al. 2015; X. Yang et al. 2015). Despite these findings, there is still no
published literature on the role of EHD2 in TNBC, although previous studies have
shown EHD2 mRNA expression to be significantly higher in caveolae-rich basal breast
cancer cell lines and TNBC patient samples (Györffy et al. 2010; Neve et al. 2006).
Understanding the regulatory role of EHD2 in caveolae-mediated membrane repair and
protection processes in triple-negative breast cancer can provide a framework for
potential new therapy targets that translate into novel treatment options for triplenegative breast cancer patients. Based on our findings here, and previous reports of
caveolae expression in TNBC and the role of EHD2 in regulating caveolae dynamics, we
hypothesize that EHD2 regulates the dynamics and stability of caveolae required for
plasma membrane repair and protection in triple-negative breast cancer. We also
hypothesize that EHD2-mediated regulation of caveolae is essential for the most
aggressive and difficult to treat types of TNBC.
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I.2 Figures
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Figure 1.1
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Figure 1.1 Breast cancer is the most common cancer among women. Ten leading cancer
types for the estimated new cancer cases and deaths by sex, United States, 2017, are
shown on this table. Estimates are rounded to the nearest 10 and cases exclude basal cell
and squamous cell skin cancers and in situ carcinoma except urinary bladder.
Used with permission from Siegel et al. (Siegel, Miller, and Jemal 2017)
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Figure 1.2
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Figure 1.2 Breast cancer pathogenesis and histologic vs. molecular subtypes. The
clinical breast cancer molecular subtypes (luminal A, luminal B, HER2+, and triplenegative) are defined by the phenotypes and gene expression patterns they share with
normal epithelial cells in the mammary duct. Specifically, luminal subtypes share
characteristics with luminal cells and the triple-negative subtype shares characteristics
with basal/myoepithelial cells.
Used with permission from McMaster Pathophysiology Review, 2012
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Figure 1.3
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Figure 1.3. Analysis of caveolin 1 and 2 expression in normal breast by
immunofluorescence. Normal breast ducts (A and B) and terminal duct-lobular units (C
and D) display strong expression of caveolin 1 (A and C, green) and 2 (B and D, green)
in myoepithelial cells, which also co-express p63 (A, B, C and D, red). Note that within
breast ducts and lobules, caveolins 1 and 2 are expressed in similar cell populations (i.e.,
myoepithelial cells). In addition, caveolin are expressed in fibroblasts and endothelial
cells. In E and F, please note the co-expression of caveolin 2 (E and F, green) and αsmooth muscle actin (E and F, red) in normal breast myoepithelial cells. In vessels,
asmooth muscle actin is expressed in pericytes (E and F, red, arrow), whereas caveolin 2
is expressed in endothelial cells (E and F, green, arrowheads)
Used with permission from (Savage et al. 2008)
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Figure 1.4
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Figure 1.4. Models of how caveolae may protect the plasma membrane from damage.
(A) Increased membrane tension results in cavin 1-associated coats detaching from the
membrane. Consequently, caveolae flatten, which increases the surface area and
prevents membrane rupture. Disassembled complexes contain subpopulations of cavin 1
alone or bound to either cavin 2 or cavin 3. (B) Wounding of the membrane results in the
formation and clustering of caveolae at the site of damage. The lesion is then removed
by internalization of the caveolae, which reseals the membrane.
Used with permission from (Cheng and Nichols 2016).
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Figure 1.5
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Figure 1.5. Structure and regions of EHD2. a, Domain structure of EHD proteins
(numbering from mouse EHD2 amino acids). b, Helical domain. Organizes scaffolding
with dimeric G-domain to help form scissor shape c, G-domain. Mediates
oligomerization and contains nucleotide-binding site similar to the G-domain of
dynamin. d, EH-domain. The EH-domain interacts with proteins containing Asn-ProPhe (NPF) motifs. e, Ribbon-type presentation of the EHD2 dimer (PDB code 2QPT).
One molecule is colored according to the secondary structure (helices in red, β-strands
in green) and the other according to the domain structure (see Fig. 1a). GPF and NPF
motifs are indicated.
Adapted and used with permission from Daumke et al. (Daumke et al. 2007)
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Figure 1.6
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Figure 1.6. EHD protein expression in normal mouse tissues. An 18 week-old male and
female C57BL/6 mouse were sacrificed and organs were removed and lysed in tissue
lysis buffer. Aliquots of 100 µg tissue lysate were separated using 8% SDS-PAGE and a
Western blot was performed using antibodies raised against human EHD proteins. The
membrane was serially stripped and reprobed beginning with both EHD1 and EHD4,
followed by EHD2, EHD3 and Hsc70 antibodies. The * denotes bands that bled through
from the previous blot following stripping. Differential mobility of Hsc70 may represent
tissue specific isoforms. Blots shown have exposure times of less than 10 seconds, upon
longer exposures, most EHD proteins can be seen in each organ shown. Relative
molecular weight (MW) markers are indicated in kiloDaltons (kD). As a loading control,
Hsc70 was blotted. M. gland – mammary gland
Used with permission from (George et al. 2007)
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Figure 1.7
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Figure 1.7. Schematic model illustrating the proposed steps involved in the
mechanistic cycle of EHD2. Binding of ATP nucleotide enables membrane insertion in
the open conformation. ATP hydrolysis enables detachment of the protein from the
membrane. These two steps allow EHD2 to oligomerize when bound to the membranes,
but not in solution. The energy that is necessary to deform the membrane is defined by
the bending modulus (∼12 kcal/mol for a typical lipid bilayer) (30). It is interesting to
note that this energy appears to be drawn from the association of EHD2 into membranebound oligomers and not from ATP hydrolysis. Thus, the hydrolysis may primarily
control the kinetics of the dissociation of the protein scaffold, which is important for a
tight regulation of the process.
Used with permission from (Hoernke et al. 2017)
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Figure 1.8
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Figure 1.8. A model on the role of oligomer formation and the ATP cycle in EHD2
association with caveolae and dynamic exchange. (1) Newly synthesized EHD2 dimers
bind ATP and are subsequently targeted to the plasma membrane via ionic interactions
with negatively charged lipids. (2) Upon lipid binding, EHD2 dimers assemble into 60–
75S oligomers via interactions of EH domain and KPF/NPF motifs in adjacent EHD2
dimers. (3) Association of EHD2 complexes with caveolae requires ATP hydrolysis,
which may be stimulated at caveolae. (4) EHD2 proteins undergo dynamic exchange at
caveolae, which requires a new cycle of ATP binding and hydrolysis. EHD2 mediates a
link to actin fibers that run in close proximity to caveolae.
Used with permission from (Stoeber et al. 2012)
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Figure 1.9
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Figure 1.9. Model of membrane repair. Upon plasma membrane injury, repair proteins
localize to the site of damage and actin reorganizes, facilitating membrane repair.
Annexins A1, A2, and A6 form a repair cap at the membrane lesion. Dysferlin (DYSF),
MG53, BIN1, and EHD participate in forming a shoulder that abuts this repair cap. PIP2
and PS localize adjacent to the repair cap at the shoulder.
Used with permission from (Demonbreun et al. 2016)
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II.1 Materials and Methods
Cell culture:
All breast cancer cell lines were obtained from ATCC and cultured in complete α-MEM
medium with 10% fetal bovine serum, 10 mM HEPES, 1 mM each of sodium pyruvate,
nonessential amino acids and L-glutamine, 50 µM 2-ME, and 1% penicillin/
streptomycin (Life Technologies, Carlsbad, CA). The TNBC cell lines BT549 and HS578t
were cultured in α-MEM medium supplemented as above and with 1 μg/mL
hydrocortisone and 12.5 ng/mL epidermal growth factor (Sigma-Aldrich, St. Louis, MO).
For retroviral overexpression of control and EHD2 shRNA, HEK-293T cells were
transfected with pQCXIX-RT3GEP vectors harboring control shRNA or EHD2 shRNAs
(Fellmann et al. 2013) together with packaging vectors, and supernatants used to infect
breast cancer cell lines followed by selection in puromycin. Cell lines were regularly
tested for mycoplasma. Cell lines were not continuously cultured for >3 months.

Reagents
Bovine serum albumin (cat. # A7906-100G), paraformaldehyde (cat. # 158127-500G),
sodium orthovanadate (Na3VO4, cat # S6508-50G), sodium deoxycholate (cat # D6750100G), and Triton X-100 (cat. # 93418) were from Sigma-Aldrich (St. Louis, MO). Hema
staining solutions (cat. # 23-123919), sodium fluoride (NaF, cat # S299-500), sodium
chloride (NaCl, cat # S271-10), and Tris (cat BP152-5) were from Fisher Chemicals.
EDTA-free protease inhibitor cocktail (cat. # 4693159001) was from Roche. ECL
development reagent (cat. # 32106), BSA for bicinchoninic acid assay (cat # 23209), and
PMSF (cat # 36978) were from Thermo-Scientific. Penicillin/streptomycin (cat. # 15140-
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122) and fetal bovine serum (FBS) (cat. # 10427-028; lot # 1662765A120-01) were from Life
Technologies. Alpha-MEM (cat. # SH30265.01) and DMEM/F12 (cat. # SHO30023.01)
were from GE Life Sciences.

Antibodies for western blot
Anti-HSC70 (cat. #sc-7298) and anti-caveolin-1 (cat # sc-894) were from Santa Cruz
Biotechnology. In-house generated Protein G-purified rabbit polyclonal anti-EHD1
antibody, and rabbit anti-EHD2, anti-EHD3 and anti-EHD4 antisera were used as
described previously (Rainey et al., 2010). Secondary antibodies for immunoblotting
included horseradish peroxidase (HRP)-conjugated Protein A or HRP-conjugated rabbit
anti-mouse antibody (Invitrogen, Carlsbad, CA).

Antibodies for immunofluorescence (IF)
Anti-caveolin-1 (cat. # sc-53564) was from Santa Cruz Biotechnology; anti-EHD1 (cat. #
ab109311) was from Abcam. Affinity-purified rabbit polyclonal rabbit anti-EHD2 was
used as described previously (Rainey et al., 2010). Secondary fluorochrome-conjugated
antibodies were from Life Technologies.

Mouse models
Ehd1-null mice were maintained on mixed 129; B6 background (Rainey et al. 2010).
Single nucleotide polymorphism (SNP) analysis (DartMouse, Lebanon, NH) revealed
these to have ~70% contribution from the C57BL/6 genome (Figure 2.1). Breeders were
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maintained on high-fat chow (# 2019, Harlan Laboratories Inc., Madison, WI). Genomic
DNA was extracted from adult tail tips with KAPA genotyping kits (KAPA Biosystems).
For the mammary gland developmental timepoint experiments, mating was set up in
the evenings, and vaginal plugs were detected the following morning. The noon of the
day of vaginal plug detection was considered Pregnancy day 0.5. Female mice were
euthanized by CO2 asphyxiation at the indicated time points followed by cervical
dislocation, and whole inguinal mammary glands were harvested. Mammary glands
were fixed at RT in 10% neutral-buffered formalin (NBF) for 48 hours, transferred to 70%
ethanol prior to paraffin embedding, and sectioned at 4-6 μm. Sections were stained
with hematoxylin and eosin (H&E). IHC for anti-EHD2 was performed according to the
IHC protocol. Brightfield images were captured using an EVOS FL Auto microscope.
Cell Lysates: Cells were either lysed in RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1% Triton-X-100, 0.05% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 10 mM NaF, and 1 mM sodium orthovanadate) or Triton-X-100 lysis
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Triton-X-100, 1 mM PMSF, 10 mM NaF,
and 1 mM sodium orthovanadate)(2). Lysates were rocked at 4°C for at least 1 hour or
frozen at -80°C and then centrifuged at 13,000 rpm for 20 minutes at 4°C and the
supernatants assayed for protein concentration using the BCA assay kit (Thermo Fisher
Scientific, Rockford, IL) or the Bradford assay (Bio-Rad Laboratories, Hercules, CA).
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Immunoblotting
Immunoblotting/Western blotting was performed as described (Rainey et al. 2010).
Briefly, cells were washed with ice-cold PBS and lysed in ice-cold RIPA lysis buffer or
Triton X-100 lysis buffer. The lysates were vortexed, centrifuged at 13,000 rpm for 30
minutes at 4o C, and supernatants collected. Protein quantification was done by using a
Thermo Scientific-Pierce Bicinchoninic acid (BCA) assay (cat. # 23225). 40 μg of lysate
protein per sample was resolved by SDS/PAGE and transferred to a PVDF membrane
(Millipore, cat. # IPVH00010). The membranes were blocked in TBS-0.1% Tween 20 (BIORAD, cat. # 161-0781) with 5% Bovine Serum Albumin (BSA) with 0.05% sodium azide,
incubated with the appropriate primary antibodies diluted in TBS-0.1% Tween 20
overnight at 4°C. Next, membranes were washed in TBS-0.1% Tween 20 (three times for
ten minutes) followed by a one-hour incubation with HRP-conjugated secondary
antibody at room temperature. The membrane was washed in TBS-0.1% Tween 20 (three
times for ten minutes) and ECL-based detection performed.

Immunofluorescence (IF)
Cellular immunofluorescence was performed, as previously described (Bailey et al.
2014) with minor modifications. Cells were cultured on glass coverslips and fixed with
4% PFA/PBS for 10 minutes. The cells were then blocked with 5% BSA/PBS for 60
minutes and incubated with primary antibodies in 5% BSA/PBS overnight. Cells were
then washed with PBS (three times), incubated with the appropriate fluorochromeconjugated secondary antibody for 45 minutes at room temperature (RT), washed and
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mounted using VECTASHEILD mounting medium (Vector Laboratories, Cat. # H-1400
and H-1500). Images were acquired using a Zeiss 710 Meta Confocal Laser Scanning
microscope (Carl Zeiss) using a 4x, 10x, 20x, or 63× objective with a numerical aperture
of 1.0 and appropriate filters. Merged fluorescence pictures were generated and
analyzed using ZEN® 2012 software from Carl Zeiss.
For tissue staining, rehydrated tissue sections were boiled in antigen unmasking
solution (H-3300, Vector Laboratories, Burlingame, CA) in a microwave for 20 min,
slides were cooled, washed once in PBS, and blocked in heat-inactivated 10% FBS
(SH30910.03, HyClone Laboratories, Logan, UT) for one hour at room temperature (RT).
Primary antibodies diluted in blocking buffer were added overnight at 4°C (except EHD
antibody staining, which was done at RT for an hour), slides were washed 3 times with
PBS followed by incubation with Alexa Fluor 488 or 594-conjugated donkey anti-rabbit
or anti-mouse secondary antibodies (1:200; Invitrogen, Carlsbad, CA) for one hour at RT
in the dark. For negative controls, sections were incubated in the blocking buffer
without the primary antibody. Nuclei were visualized with DAPI in antifade mounting
medium (ProLong® Gold Antifade mountant, Invitrogen, Carlsbad, CA). Fluorescent
images were captured on a Zeiss LSM-710 confocal microscope. Images were processed
using Adobe Photoshop CC software. For presentation, signal intensities were adjusted
equally for brightness and contrast between control and test images.
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Transfection Reagents and Plasmids
XtremeGENE 9 transfection reagent was from Roche Applied Science (Indianapolis, IN).
A pQCXIX-RT3GEP (Fellmann et al. 2013) shRNA construct for scrambled shRNA or
EHD2-targeted shRNA was custom-made through a commercial vendor (Mirimus)
(Figure 2.1).

Trans-well invasion assays
The cells were seeded in the top chamber of trans-well chambers with 8 μm pore size
nitrocellulose filters (Corning) in serum-free medium. Medium containing 10% FBS
served as a chemoattractant in the lower chamber. The membranes were coated with 1:2
diluted Matrigel (BD Biosciences) before seeding the cells. After 22 h, the cells on the
upper side of the membrane were removed by scraping with cotton swabs, while those
on the lower side were fixed with methanol, stained with HEMA solutions and cells
were counted. The migrated cells from the whole well were enumerated using Image J
(NIH, MD). All experiments were done in triplicates, and repeated three times.

Orthotopic xenograft tumorigenesis
5 x 106 cells mixed with 0.2 ml Matrigel (BD Biosciences) were implanted in the
mammary fat pad of 4 to 6 week-old non-pregnant female nude mice (Figure 2.2) (The
Jackson Laboratory). Three days prior to cell implantation, the mice were primed with a
subcutaneous estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research of America,
Sarasota, FL) and tumor growth monitored weekly for 12 to 14 weeks. After euthanasia,
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tumors were imaged, and formalin-fixed and paraffin-embedded for further analyses.
Tumor dimensions were measured with Vernier calipers and tumor volume calculated
as length x width x depth/2. Mice were euthanized when control tumors reached 2 cm3
in volume or showed signs of ill health, as per institutional IACUC guidelines. At the
end of the experiment, the tumor as well as liver and lung are resected, formalin-fixed
and paraffin-embedded for further analyses.

Human and animal subjects
The procurement and use of human tissues were approved by the Ethics Committee of
the University of Nottingham where the tissues are archived under the direction of our
collaborator Dr. Emad Rakha (University of Nottigham Hospital, Department of
Pathology, Breast Unit). Mouse studies were pre-approved by the UNMC Institutional
Review Board (IRB) Committee, in compliance with Federal and State guidelines.

IHC analysis of breast cancer tissue microarrays
Tissue microarrays (TMAs) corresponding to a well-annotated 971 breast cancer patient
cohort at the University of Nottingham Hospital Breast Unit were analyzed by IHC
staining with a previously described anti-rabbit EHD2 antibody (Rainey et al., 2010) that
was further validated (Figure 3.3). Of the whole series (840 cases), 759 were informative.
The expression of EHD2 was detected in the cytoplasm and/or nucleus of the malignant
cells while, in the normal parenchymal element its expression was noted in the nuclei of
epithelial cells only. For statistical analysis, expression was dichotomized using cutoff
points that were selected based on histogram distribution. The cutoff points were
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selected using median and X-tile software as follows: a H-score of zero for nuclear EHD2
and H-score of 50 for cytoplasmic EHD2 expression. Statistical analysis was performed
by using the SPSS IBM 22 statistical software. The relationship between nuclear and
cytoplasmic EHD2 expression and different clinicopathological variables was assessed
using Chi square-test. Survival curves were obtained using Kaplan–Meier method for
outcome estimation and significance determined using the log-rank test. Two-tailed Pvalues less than 0.05 we re considered significant.

Anchorage-independent growth assay
Three thousand cells were seeded in 0.3% soft agar on top of 0.6% soft agar layer in 6well plates. After two weeks, cells were stained with crystal violet and imaged under a
phase contrast microscope. The colonies in the entire wells were enumerated using
Image J (NIH, MD). All experiments were done in triplicates, and repeated three times.

Tumor-sphere assay
Cells were re-suspended in DMEM/F12 (cat. # SH30023.01, GE Lifesciences) media
supplemented with 2mM L-glutamine, 100U/ml penicillin/streptomycin, 20ng/ml EGF
(sigma), 10 ng/ml FGF (R&D Systems) and 1x B27 supplement (Gibco), and seeded at
100,000 cells/well into poly-HEMA coated 6-well plates. After one week, tumor-spheres
were imaged under a phase contrast microscope. Tumorspheres greater than 40 μm in
diameter were quantified as previously described (Shaw et al. 2012), using Image J (NIH,
MD). All experiments were done in triplicates, and repeated three times.
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Membrane repair assay
Cells were grown on coverslips and washed with PBS + 2mM Ca2+ before transferring to
phenol red free HBSS + 2mM Ca2+ containing 2 mg/ml lysine fixable 10-kDa CascadeBlue
dextran. Glass beads of about 20 mg (425-600 µm, Sigma) were sprinkled onto the cells
and the beads were rolled gently 10-12 times over the cells to induce plasma membrane
wounds. After wounding the coverslips were incubated as such at 37°C for 5 min.
Following one wash with PBS + 2mM Ca2+ buffer, cells were incubated with prewarmed
phenol red-free HBSS + 2 mM Ca2+ containing 2 mg/ml lysine fixable 10-kDA TRITC
dextran at 37°C for 5 min. The coverslips were then washed in PBS twice and fixed in 4%
PFA. The number of CascadeBlue-positive (total wounded cells) and TRITC-positive
(wounded cells which have not resealed) were counted in 20 fields in duplicate. Cells
were imaged using an EVOS FL Auto inverted microscope with 10x objective, using
DAPI and TexasRed lightcubes. The number of wounded cells that failed to reseal were
expressed as a percentage of the total wounded cells, as previously described (Defour,
Sreetama, and Jaiswal 2014).

Matrigel spheroid assay
Cells were re-suspended as a single cell suspension in media containing 50% Matrigel
and seeded at 2,000 cells/well on top of a base layer of Matrigel in an 8-well chamber
slide. TNBC cell spheroids were allowed to grow for 7 days and then imaged and
quantified. Quantification of invasive spheroids was performed by comparing the
number of spheroids with invadopodia to the total number of spheroids. Over 100 total
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spheroids were counted per well and all experiments were done in triplicates and
repeated three times.

Statistics
P-values were calculated by using an unpaired Student’s t-test and the threshold of
significance was p<0.05. Data is shown graphically as mean ± SEM (error bars).
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II.2 Figures
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Figure 2.1

40
Figure 2.1 Retroviral plasmid for EHD2 shRNA. a, Retroviral vector used to form
EHD2 shRNA. b, Constitutive shRNA expression vector obtained from Mirimus, Inc.
The shRNA is embedded in an enhanced miR-30 backbone termed miR-E.
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Figure 2.2
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Figure 2.2 Orthotopic injection of breast cancer cells. TNBC cell lines (MDA-MB-231,
BT549, or HS578T) with EHD2 or control shRNA were concentrated into 5 x 106 cells per
100uL suspensions of 50% Matrigel. Cell suspensions were implanted into the inguinal
mammary gland of 4 to 6-week old non-pregnant female nude mice. Tumors were
detected 3 weeks after implantation and followed for 11-13 weeks.
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Chapter III: Results
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III.1 Results
A. EHD2 and caveolin-1 are expressed within the myoepithelial/basal layer of
the mammary duct
As described previously (George et al. 2007), EHD protein expression is
differential throughout many murine tissues (Figure 1). Although EHD2 protein
expression is high in western blots of total murine mammary gland lysates, we sought to
further characterize the exact the expression and location of EHDs within this tissue. We
initiated studies by first reconfirming the expression pattern of EHDs within total
mammary gland lysate of wild type female C57BL/6 mice (Figure 3.1 A). Our results
showed that EHD2 was indeed the highest expressed member of the EHD family of
proteins within the murine mammary gland. Consistent with previous analysis (George
et al. 2007), EHD 1 and EHD4 were both expressed while EHD3 was not observed.
We next sought to determine the localization of the EHDs expressed within the
mammary gland. To accomplish this, we performed confocal immunofluoresence on
formalin-fixed, paraffin-embedded (FFPE) mammary gland sections from twelve-weekold female C57BL/6 mice. Due to issues with antibody specificity, the localization of EHD4
could not be accurately observed. However, we found that EHD2 was specifically and
consistently expressed in the myoepithelial/basal layer of the mammary duct and the
adipocytes of the surrounding stroma (Figure 3.1 B). EHD1, on the other hand, was barely
detectable within the mammary duct and surrounding stroma, except for the subcapsular
sinus region of the mammary lymph node (Figure 3.2 A, Figure 3.2 B). Although striking,
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these findings make sense given that the subcapsular sinus region contains CD-169+
macrophages with high expression of CSF-1 receptor(Shiota et al. 2016), and that EHD1
plays a crucial role in regulating the endocytic trafficking of CSF-1 receptor within
macrophages(Cypher et al. 2016).
To confirm the specificity of our EHD2 antibody, we compared the wild type
mammary gland expression with a newly developed EHD2-/- C57BL/6 mouse developed
by GenOway. Western blot and confocal immunofluoresence confirmed that our EHD2
antibody was indeed specific (Figure 3.3 A, Figure 3.3 B). Interestingly, knockout of EHD2
in the EHD2-/- female mice led to an increase in EHD1 expression within compartments
typically expressing EHD2 (Figure 3.3 C). This suggests that EHD1 serves a functionally
redundant role to EHD2 in these specific mammary ductal compartments, consistent with
previous literature regarding the functionally redundant roles of EHDs in other tissues
(Rainey et al. 2010; Sengupta et al. 2009; George et al. 2011). Additionally, the upregulation
of EHD1 in response to EHD2 knockout may explain why EHD2-/- mice do not exhibit any
overt phenotype (data not shown). Despite these EHD1 findings, we elected to focus on
EHD2 expression within the mammary gland.
While EHD2 was highly expressed within the myoepithelial/basal layer of 12week old mice, we sought to confirm its localization in human tissue. Using human breast
tissue sections, we performed immunohistochemical staining to confirm EHD2
localization in human mammary ducts is consistent with what we observed in mice. We
found that EHD2 was indeed localized to the myoepithelial/basal layer in the mammary
duct of human breast tissue (Figure 3.4 A).
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Considering the highly dynamic nature of the mammary gland (Inman et al. 2015),
we decided to investigate the consistency of EHD2 expression and localization during
different points of mammary gland development. Using immunohistochemical staining,
we found that EHD2 was consistently localized to the myoepithelial/basal layer of the
murine mammary duct throughout puberty, adulthood, pregnancy, lactation, and
involution (Figure 3.4 B).
Given the established role of EHD2 in caveolar dynamics (Stoeber et al. 2012;
Moren et al. 2012), we suspected that the specific and consistent expression of EHD2
within the myoepithelial/basal layer of the mammary duct is relevant to caveolae function
within these compartments. Accordingly, we found that caveolin-1 expression is also high
within these same compartments (Figure 3.5 A) but knockout of EHD2 did not alter
caveolin-1 levels (Figure 3.5 B), consistent with previous literature (Mercier et al. 2009;
Aoki et al. 2011; Pinilla et al. 2006; Stoeber et al. 2012).

B. EHD2 and caveolin-1 are co-expressed in Basal B and Triple-Negative
breast cancer cell lines
We then selected a large panel of human breast cancer cells and performed
biochemical analysis to determine the protein expression of EHD2. We found that EHD2
was mainly expressed in TNBC cell lines and largely absent from the ER+/PR+ and HER2+
cell lines (Figure 3.6 A). EHD2 expression was also observed in the basal non-malignant
mammary epithelial cell lines, 76Ntert and MCF10a.
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Using the online database Gene expression-based Outcome for Breast cancer
Online (GOBO) (Ringnér et al. 2011), we found that EHD2 mRNA expression was
significantly higher in Basal B breast cancer lines compared to the Basal A and HER2+ cell
lines in the panel (Figure 3.6 B). Moreover, caveolin-1 mRNA expression was also
significantly higher in the Basal B cell lines (Figure 3.6 C). The Basal B subtype is the most
invasive breast cancer subtype and is are considered to be triple-negative (Neve et al.
2006). When analyzing individual cell lines by the same method, we identified cell lines
with high EHD2 mRNA expression (Figure 3.7 A) and high co-expression of EHD2 and
caveolin-1 mRNA within the Basal B subtype (Figure 3.7 B).
Next, we selected a few cell lines to determine if EHD2 mRNA levels correlate with
EHD2 protein levels. We found that EHD2 mRNA correlates with protein levels in our
selected breast cancer cell lines (Figure 3.8 A), and EHD2 protein was high in our selected
Basal B cell lines (Figure 3.8 B). Since we are studying the role of EHD2 in regulating
plasma membrane associated caveolae, we used confocal microscopy to determine in our
selected breast cancer cell lines expressed EHD2 at the cell membrane. We observed the
majority of EHD2 localized at the plasma membrane in our EHD2 positive cell lines
(Figure 3.8 C). To confirm the in vitro expression of EHD2 in our selected TNBC cell lines,
we injected MDAMB468, Hs578t, or MCF7 cells into the inguinal mammary glands of
NSG mice and harvested the tumors after 6 weeks. We then used immunohistochemical
analysis to confirm that EHD2 was expressed in the tumors generated from the Basal B
cell line (Hs578t) and not in the basal A (MDAMB468) or luminal cell line (MCF7) (Figure
3.8 D).
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Once we determined the extent of EHD2 expression within our selection of human
breast cancer cell lines, we sought to determine the extent of EHD2 co-expression and colocalization with caveolin-1. Although the regulation of caveolae via EHD2 is well
established in the literature (Briand et al. 2014; Stoeber et al. 2012; Morén et al. 2012;
Hansen, Howard, and Nichols 2011; Simone, Naslavsky, and Caplan 2014), there is
nothing published that demonstrates the relationship between EHD2 and caveolae in
breast cancer or the mammary gland. Moreover, the role of caveolae in breast cancer is
unclear and seems to function as a tumor promoter in some subtypes while serving as a
tumor suppressor in others (Feldman et al. 2015; Savage et al. 2008; Mercier and Lisanti
2012). Since caveolin-1 is the essential structural protein of caveolae, we used a large panel
of breast cancer cell lines to ascertain the level of EHD2 and caveolin-1 co-expression. We
found EHD2 and caveolin-1 protein expression to be mutually exclusive throughout our
selected cell lines (Figure 3.9 A), indicating that EHD2 serves an important role for
caveolae in breast cancer. Since EHD2 tends to be more highly expressed in TNBC and
caveolae expression is believed to serve as a tumor promoter in TNBC (Elsheikh et al.
2008), we performed confocal immunofluorescence on EHD2-expressing TNBC cell lines
to determine the extent of co-localization. We observed near perfect co-localization of
EHD2 and caveolin-1 in MDA-MB-231, BT549, and Hs578t cell lines (Figure 3.9 B),
showing that EHD2 is localizing to caveolae in breast cancer cell lines for the first time.
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C. EHD2 and caveolin expression is associated with lower survival in patients
with triple-negative breast cancer
After we determined that mRNA expression of EHD2 and caveolin-1 correlates to
protein expression in human breast cancer cell lines, we sought to analyze co-expression
of EHD2 mRNA with caveolin-1 (CAV1) and caveolin-2 (CAV2) mRNA in human breast
cancer samples. We used bc-GenExMiner (Jézéquel et al. 2013; Jézéquel et al. 2012), an
online database of mRNA expression from over 5,000 breast cancer samples, to determine
the Pearson’s pairwise correlation for EHD2 mRNA in relation to CAV1 and CAV2
expression across all tumor samples (Figure 3.10 A). We found EHD2 mRNA expression
to be significantly positively correlated with CAV1 (Figure 3.10 B) and CAV2 (Figure 3.10
C).
Since we observed that EHD2 mRNA is positively correlated with CAV1 and
CAV2 mRNA in breast cancer cases, we next examined the effect of EHD2, CAV1, and
CAV2 mRNA expression in relation to survival of human breast cancer patients. Using
KM-plotter (Györffy et al. 2010), an online database of mRNA expression levels in relation
to survival in breast cancer patients, we found that high EHD2 mRNA expression was
significantly associated with lower probability of survival in patients with basal tumors,
but not across all breast cancer cases (Figure 3.11 A). Interestingly, the same pattern in
survival was seen for CAV1 (Figure 3.11 B) and CAV2 (Figure 3.11 C) mRNA expression.
Using GOBO (Ringnér et al. 2011), we were able to screen for probability of survival for
breast cancer patients with either combined low or combined high mRNA expression for
EHD2, CAV1, and CAV2. Once again, we found that high combined EHD2, CAV1, and
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CAV2 mRNA expression was significantly associated with lower probability of distant
metastasis-free survival (DMFS) in patients with basal tumors, but not in across all patient
tumor samples (Figure 3.12 A and Figure 3.12 B).
Although we determined mRNA expression to be a good indication of EHD2
protein expression in breast cancer cell lines, we wanted to determine if EHD2 protein
expression was in fact associated with TNBC and caveolin expression in patient cases. In
a blind study, we performed immunohistochemical staining using an anti-EHD2 on a
tumor microarray (TMA) of a well-characterized cohort of 880 breast cancer patient
samples that had previously been assessed for caveolin-1 and caveolin-2 protein
expression(Elsheikh et al. 2008). The stained slides were then scored by pathologists and
categorized for expression levels of nuclear and cytoplasmic EHD2 (Figure 3.13 A). The
protein expression and localization scores were then compared to breast cancer specific
survival (BCSS) for the patient cohort (Figure 3.13 B). High cytoplasmic expression was
significantly associated with lower probability of survival for all cases and markers for
poorer prognosis (Table 3.1). Interestingly, high nuclear expression was significantly
associated with higher probability of survival and markers for better prognosis (Table 3.1).
The unexpected nuclear expression of EHD2 and its association with higher survival
could explain the previously observed discrepancy in survival probability between all
tumor cases and basal tumors with regards to mRNA expression. In fact, when the
samples are scored for only high or low/negative cytoplasmic EHD2 expression (Figure
3.14 A), high EHD2 expression is significantly associated with TNBC (Figure 3.14 B) and
lower survival (Figure 3.14 C). Conversely, nuclear expression is associated with luminal
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markers (Table 3.1). Consistent with our previous findings in breast cancer cell lines and
mRNA expression data of human breast cancer patients, high EHD2 cytoplasmic
expression is associated with Caveolin-2 expression (Table 3.2). Despite the interesting
finding regarding EHD2 expression within the nucleus, we decided to focus on
cytoplasmic EHD2 expression and its association with TNBC.

D. shRNA-mediated knockdown of EHD2 leads to reduced tumorigenicity
and invasiveness of Triple-negative breast cancer in vitro and in vivo
Using retroviral transduction, we generated three TNBC cell lines (MDA-MB-231,
BT549, and Hs578t) with stable EHD2 shRNA and control shRNA (Figure 3.15 A). We did
not find any significant change in proliferation in TNBC cells with EHD2 shRNA (Figure
3.15 B). However, we found significant reduction in invasion in TNBC cells with EHD2
shRNA compared to controls (Figure 3.15 C). Additionally, cells with EHD2 shRNA had
lower tumorigenicity, as indicated by fewer soft-agar colonies (Figure 3.16) and fewer
tumorspheres in non-adherent conditions (Figure 3.17).
Next, we sought to examine the effect of EHD2 depletion in TNBC tumors in vivo.
We performed xenograft injections into the inguinal mammary gland of 4-week-old nude
mice. After two weeks, palpable tumors were observed in all mice. The tumor volume of
each mouse was measure every week until the study was terminated in week eleven. We
found that EHD2 knockdown dramatically halted tumor volume and progression,
compared to mice with control shRNA in BT549 (Figure 3.18 A and Figure 3.18 B) and
HS578t tumors (Figure 3.19 A and Figure 3.19 B). Additionally, EHD2 knockdown tumors

52
had a decrease in proliferation, per immunohistochemical staining of proliferative marker
Ki-67 (Figure 3.20). We then performed confocal microscopy to verify the knockdown of
EHD2 in the tumors with EHD2 shRNA (Figure 3.21).
Following the observation of the dramatic reduction in tumor, we set forth to
determine the extent of metastasis associated with EHD2 knockdown in TNBC cells.
Unfortunately, BT549 and HS578t cells are not reliably capable of metastasis. Instead, we
performed xenograft injections of MDA-MB-231 cells as described above. We found that
EHD2 knockdown in MDA-MB-231 cells led to a dramatic decrease in final tumor volume
and a decrease in lung metastasis (Figure 3.22)

E. Triple-negative breast cancer cells require EHD2 for growth in extracellular
matrix and plasma membrane repair
Although a decrease in tumor growth and metastasis was expected in TNBC
tumors with EHD2 shRNA, the dramatic decrease in tumor volume across all TNBC cell
lines led us to believe that EHD2 was necessary to an essential function for tumor cells in
vivo. This lead us to once again investigate bc-GenExMiner to determine what other
proteins EHD2 was correlated with in breast cancer patient samples and the functions
those proteins may serve. By investigating gene ontology correlations, we found that
EHD2 expression was tightly correlated with cellular components associated with the
extracellular matrix, extracellular region, basement membrane, focal adhesion, and other
functions associated with the plasma membrane (Table 3.3). This finding led us to next
examine the growth of EHD2-knockdown TNBC cells within a basement membrane
extract. To examine this, we used Matrigel, a commercially available mixture of various
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extracellular matrix components. Matrigel is commonly used to mimic the ECM that
tumors grow in in vivo (Ortega-Cava et al. 2011; Dimri et al. 2007). We found that EHD2
knockdown led to dramatic reduction in invasive morphology in MDA-MB-231 (Figure
3.23 A) and BT549 (Figure 3.24 A) cells grown in Matrigel. The EHD2 knockdown cells
had fewer invasive projections, often referred to as invadopodia (Hashimoto et al. 2004),
in both MDA-MB-231 (Figure 3.23 B) and BT549 cells (Figure 3.24 B).
Given the well-established role of EHD2 in regulating the dynamics of caveolae
and the more recent discoveries that caveolae play an important role in membrane repair
and invadopodia formation in cancer (Yamaguchi et al. 2009; H. Yang et al. 2016; Stoeber
et al. 2012), we sought to determine the effect of EHD2 knockdown on membrane repair
in TNBC cells. To examine membrane repair, we used a bulk wounding assay with glass
beads and various cytoplasm staining dyes. Briefly, cells were plated on coverslips and
then wounded via glass bead rolling. They were then incubated with a CascadeBlueconjugated dextran to label cells with damaged membranes. Cells were then allowed to
reseal their membranes and then incubated with a TRITC-conjugated dextran to label cells
that failed to repair (Figure 3.25 A). Using this assay, we found that EHD2 knockdown
resulted in a significantly higher percentage of cells with failed membrane repair in MDAMB-231, BT549, and HS578t cells (Figure 3.25 B). These findings suggest that EHD2
regulation of caveolae is essential to membrane repair processes in TNBC cells.
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III.2 Tables
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Table 3.1
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Table 3.1. Table showing the relationship between EHD2 subgroups and the other
markers. Of the whole series (840 cases), 759 were informative. The expression of EHD2
is detected in the cytoplasm and/or nucleus of the malignant cells while, in the normal
parenchymal element its expression is noted in the nuclei of epithelial cells only. For
statistical analysis, expression was dichotomized using cutoff points that were selected
based on histogram distribution. The cutoff points were selected using median and Xtile software as follows: an H-score of zero for nuclear EHD2 and H-score of 50 for
cytoplasmic EHD2 expression.
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Table 3.2
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Table 3.2 continued
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Table 3.2. Association with clinicopathological parameters. Of the whole series (840
cases), 759 were informative. The expression of EHD2 is detected in the cytoplasm
and/or nucleus of the malignant cells while, in the normal parenchymal element its
expression is noted in the nuclei of epithelial cells only. For statistical analysis,
expression was dichotomized using cutoff points that were selected based on histogram
distribution. The cutoff points were selected using median and X-tile software as
follows: an H-score of zero for nuclear EHD2 and H-score of 50 for cytoplasmic EHD2
expression. Nuclear and cytoplasmic EHD2 expression showed contrasting associations
with other variables with loss of nuclear expression and or cytoplasmic expression
associated with variables characteristic of poor prognosis and shorter survival (tumor
suppressor gene-like effect). There were associations between loss of nuclear EHD2
expression and poor prognostic variables including large tumour size, high tumour
grade with frequent mitoses and high Ki-67, positive vascular invasion and high
Nottingham Prognostic Index (NPI) scores. Nuclear EHD2 showed positive associations
with good prognostic biomarkers including hormone receptors (ER, PR, AR) and other
markers characteristics of the luminal class such as muc1, BEX1, nuclear BRCA1 and
RAD51, FHIT, FOXA1 and E-cadherin. Loss of nuclear EHD2 expression was associated
with basal-like molecular class biomarkers including CK5, CK 17 and Ki-67, and with
triple negative phenotype and biomarkers associated with EMT including loss of Ecadherin and expression of N-cadherin. Nuclear EHD2 was associated with AKT and
PI3K and with ERK (pan-ERK, phospho-ERK and p38). On the other hand, cytoplasmic
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EHD2 expression showed positive association with poor prognostic markers including
high grade, high mitotic rate and with basal-like biomarker (CK5) and the apoptosis
marker Bcl2.
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Table 3.3
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Table 3.3. EHD2 association with caveolin-1 status. Cases were defined based on the
dual expression (CYTO and NUC). Then cases with any nuclear staining were excluded
(Double CYT and NUC positive as well as the NUC positive CYTO Negative) cases.
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Table 3.4
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Table 3.4. EHD2 association with caveolin-2 status. Cases were defined based on the
dual expression (CYTO and NUC). Then cases with any nuclear staining were excluded
(Double CYT and NUC positive as well as the NUC positive CYTO Negative) cases.
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Table 3.5
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Table 3.5. EHD2 mRNA aassociation with extracellular-mediated cellular processes in
TNBC patients. Using bc-GenExMiner v 4.0 (Jézéquel et al. 2013; Jézéquel et al. 2012),
we performed gene correlation exhaustive analysis to identify genes best correlating
positively to EHD2 in over 700 TNBC patient samples. We then sorted the results into
their associated Gene Ontology term enrichments.
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III.3 Figures
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Figure 3.1
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Figure 3.1. EHD2 expression in the mammary duct is localized to the myoeptheilium.
a, Immunoblot analysis of EHD levels in normal murine mammary gland; Hsc70 loading
control is shown on the bottom panel. b, Immunofluorescence images of normal mouse
mammary gland. Top row is stained with anti-cytokeratin 8 (CK8) (green) and antiEHD2 (red) antibodies. Bottom row is stained with anti-alpha smooth muscle actin
(SMA) (green) and anti-EHD2 (red). Both rows were counterstained with 4,6-diamidino2-phenylindole (DAPI, to stain DNA; blue). Scale bars, 20μm.
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Figure 3.2
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Figure 3.2. EHD1 expression in the mammary gland is primarily localized to the
subcapsular sinus of the mammary lymphnode. a, Immunofluorescence images of
normal mouse mammary gland stained with anti-EHD1. White arrows indicate
subscapular sinus region of mammary lymph node. Scale bar: 200 µm. b,
Immunofluorescence images of normal mouse mammary gland stained with anti-EHD1.
Scale bar: 100 µm.

72
Figure 3.3
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Figure 3.3. Confirmation of EHD2 knockout and increased EHD1 expression in the
mammary gland of EHD2 -/- mice. a, Immunoblot analysis of EHD levels in normal
murine mammary gland and EHD2 null mammary gland; Hsc70 loading control is
shown on the bottom panel. b, Immunofluorescence images of 12-week old female
inguinal mammary glands of EHD2+/+ mice (top row) or EHD2 -/- mice (bottom row)
stained with anti-EHD2 (left panel) and DAPI (middle panel). Merged images of EHD2
and DAPI show lack of EHD2 expression in EHD2 -/- mice. (right panel). Scale bars, 200
μm. b, Immunofluorescence images of 12-week old female inguinal mammary glands of
EHD2+/+ mice (top row) or EHD2 -/- mice (bottom row) stained with anti-EHD1 (left
panel) and DAPI (middle panel). Merged images of EHD2 and DAPI show lack of EHD2
expression in EHD2 -/- mice. (right panel). Scale bars, 100 μm.
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Figure 3.4
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Figure 3.4. EHD2 is consistently expressed and localized to the myoepithelial/basal
layer of the mammary duct. a, Immunohistochemical staining of EHD2 in normal
human breast tissue sections. Selected area demonstrates the localization of EHD2
within the human myoepithelial/basal layer. b, Immunohistochemical analysis of EHD2
in murine mammary gland sections throughout various timepoints of development.
Images are arranged to show the dynamic cycle of mammary gland development. Scale
bars, 100 μm.
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Figure 3.5
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Figure 3.5. EHD2 and caveolin-1 occupy the same compartments of the mammary
gland. a, Immunoblot analysis of EHD levels and caveolin-1 levels in normal murine
mammary gland, EHD2, EHD1, and EHD4 null mammary gland; Hsc70 loading control
is shown on the bottom panel. b, Immunofluorescence images of 12-week old female
inguinal mammary glands of mice stained for EHD2 (red, top row) or caveolin-1 (red,
bottom row), and smooth muscle actin (green), and DAPI (blue). Scale bars, 200 μm.
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Figure 3.6
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Figure 3.6. EHD2 and caveolin-1 are primarily expressed in triple-negative breast
cancer cell lines. a, Immunoblot analysis of EHD levels in non-tumorigenic
immortalized mammary epithelial cells (76Ntert, MCF10a), luminal A breast cancer cell
lines (ER+/PR+), luminal B breast cancer cell lines (ER+/PR+, ErbB2+), HER2+ breast
cancer cell lines (ErbB2+), and Triple-negative breast cancer cell lines (ER-/PR-, ErbB2-);
Hsc70 loading control is shown on the bottom panel. b, Box-and-whisker plot of EHD2
mRNA expression levels in Basal A, Basal B, and Luminal cell lines. c, Box-and-whisker
plot of caveolin-1 mRNA expression levels in Basal A, Basal B, and Luminal cell lines.
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Figure 3.7
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Figure 3.7. Cell lines with high EHD2 mRNA expression and high EHD2 and
caveolin-1 mRNA expression. a, Relative mRNA expression of EHD2 across individual
basal A, basal B, and luminal cell lines. b, Relative mRNA expression of EHD2 and
caveolin-1 across individual Basal A, Basal B, and Luminal cell lines.
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Figure 3.8. EHD2 mRNA expression correlates with protein expression in breast
cancer cell lines. a, EHD2 mRNA is highly expressed primarily within basal-like and
triple-negative cell lines. b, EHD2 protein is highly expressed within basal-like and
triple-negative cell lines. c, Immunofluorescence microscopy of EHD2 (red) localizes
primarily to the plasma membrane of basal-like and triple-negative cell lines. DAPI
(blue) was used to stain the nucleus. Scale bar indicates 50 µm. d, immunohistochemical
staining of EHD2 in FFPE sections from xenograft tumors shown at 10x magnification.
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Figure 3.9
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Figure 3.9. EHD2 is co-expressed and co-localizes with caveolin-1 in breast cancer
cells. a, Western blot analysis of multiple breast cancer cell lines shows that EHD2 is
expressed in triple-negative breast cancer (TNBC) and HER2 positive (HER2+) cells
expressing caveolin-1. Non-tumorigenic cell lines (76Ntert and 16A5) also express EHD2
and caveolin-1. b, Immunofluorescence of anti-EHD2 (red) and anti-caveolin-1 (green) in
TNBC cell lines shows co-localization of both proteins. Scale bar indicates 100 µm.
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Figure 3.10
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Figure 3.10. EHD2 mRNA expression positively correlates with caveolin-1 and
caveolin-2 mRNA expression in human breast cancer. a, Pearson’s pairwise correlation
heatmap of EHD2, caveolin-1 (CAV1), and caveolin-2 (CAV2) mRNA expression across
5,277 human breast cancer samples. Red hue indicates strong positive correlation. b,
Pearson’s pairwise correlation plot of EHD2 and CAV1 mRNA expression for 5,277
human breast cancer samples. c, Pearson’s pairwise correlation plot of EHD2 and CAV2
mRNA expression for 5,277 human breast cancer samples. Data obtained from bcgenExMiner.
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Figure 3.11. EHD2 and caveolin mRNA expression is associated with lower
probability of survival in basal breast cancer. a, Kaplan-Meier survival curve for all
tumors (left panel) and basal tumors (right panel) for low EHD2 mRNA (black) and high
EHD2 mRNA (red) b, Kaplan-Meier survival curve for all tumors (left panel) and basal
tumors (right panel) for low CAV1 mRNA (black) and high CAV1 mRNA (red). c,
Kaplan-Meier survival curve for all tumors (left panel) and basal tumors (right panel) for
low CAV2 mRNA (black) and high CAV2 mRNA (red). All data obtained from
kmplot.com.
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Figure 3.12. Combined EHD2, caveolin-1, and caveolin-2 mRNA expression is
associated with lower probability of survival in basal breast cancer. a, Kaplan-Meier
survival curve for distant metastasis-free survival (DMFS) percentage in all tumors for
low EHD2 mRNA (gray) and high EHD2 mRNA (red) b, Kaplan-Meier survival curve
for DMFS percentage in basal tumors for low EHD2 mRNA (gray) and high EHD2
mRNA (red)
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Figure 3.13. EHD2 protein expression and localization determines survival probability
across a cohort of 840 human breast cancer tissue samples. a, Representative images
(20x magnification) of EHD2 expression levels and nuclear/cytoplasmic localization
throughout a tumor microarray of 840 human breast cancer samples.
Immunohistochemistry staining for anti-EHD2 was performed and sent for pathologist
scoring to Nottingham, U.K. b, Kaplan-Meier survival curve for breast cancer specific
survival (BCSS) probability in all tumors scored for nuclear positive and cytoplasmic
negative (green), nuclear positive and cytoplasmic positive (red), nuclear negative and
cytoplasmic negative (blue), and nuclear negative and cytoplasmic positive (gray)
expression of EHD2 throughout 840 human breast cancer samples.
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Figure 3.14. Cytoplasmic EHD2 expression is associated with TNBC and lower
probability of survival across a cohort of 840 human breast cancer samples. a,
Representative images (20x magnification) of negative/low cytoplasmic (left) and
positive/high cytoplasmic EHD2 expression levels throughout a tumor microarray of 840
human breast cancer samples. Immunohistochemistry staining for anti-EHD2 was
performed and sent for pathologist scoring to Nottingham, U.K. b, percentage of
negative/low (gray) and positive/high cytoplasmic EHD2 samples in luminal, HER2+,
TN, and all tumors throughout a tumor microarray of 840 human breast cancer samples.
c, Kaplan-Meier survival curve for Breast Cancer Specific Survival (BCSS) probability in
all tumors scored for nuclear/low (black) and positive/high cytoplasmic expression of
EHD2 throughout 840 human breast cancer samples.
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Figure 3.15. EHD2 shRNA knockdown reduces invasiveness of TNBC cell lines in
vitro. a, Western blot analysis of EHD2 expression by MDA-MB-231, BT549, and Hs578t
cells after retroviral transduction with control or EHD2 shRNA. HSC70 was used as a
loading control. b, Representative image of transwell invasion extent for TNBC cells
with control or EHD2 shRNA. Cells were seeded in the top chamber and allowed to
invade through a Matrigel-coated membrane for 22 hours. c, Quantification of
invasiveness for TNBC cells with control or EHD2 shRNA after 22 hours. Cells were
fixed in methanol, stained with HEMA solution, and counted per high power field. * =
p < 0.05
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Figure 3.16. EHD2 shRNA knockdown reduces growth of soft-agar colonies for TNBC
cell lines. a, Representative image of soft-agar colonies for TNBC cells with control or
EHD2 shRNA. b, Quantification of the number of soft-agar colonies for TNBC cells with
control or EHD2 shRNA after two weeks. Cells were fixed in methanol, stained with
crystal violet, and counted per well. (error bar indicates s.e.m., n=3 experiments, *
indicates P<0.05, ** indicates P<0.01).
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Figure 3.17. EHD2 shRNA knockdown reduces tumorsphere formation in TNBC cell
lines. a, Representative image of tumorspheres for TNBC cells with control or EHD2
shRNA. b, Quantification of the number of tumorsphers for TNBC cells with control or
EHD2 shRNA after one week. Tumorspheres over 40 µm in diameter were counted per
well. (error bar indicates s.e.m., n=3 experiments, * indicates P<0.05, *** indicates
P<0.005).
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Figure 3.18. EHD2 shRNA-mediated knockdown reduces tumorigenicity of BT549
cells in vivo. Reduced fold change in tumor volumes in fat pads of athymic mice
injected with EHD2 shRNA cells compared to control shRNA cells. a, 5x106 BT549 cells
with control shRNA (filled dots) or EHD2 shRNA (open squares) were injected into 4week old aythmic mice, and followed for 13 weeks to estimate fold change in tumor
volume after injection (each dot or square represents an individual tumor). Each data
point is the volume of a single tumor (lines indicate median, error bars indicate
interquartile range). b, Representative images of BT549 xenograft tumors with control
shRNA (top row) or EHD2 shRNA (bottom row) from athymic mice at the experiment
endpoint. Tumors shown are representative of the median from each group.
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Figure 3.19. EHD2 shRNA-mediated knockdown reduces tumorigenicity of HS578t
cells in vivo. Reduced fold change in tumor volumes in fat pads of athymic mice
injected with EHD2 shRNA cells compared to control shRNA cells. a, 5x106 Hs578t cells
with control shRNA (filled dots) or EHD2 shRNA (open squares) were injected into 4week old aythmic mice, and followed for 11 weeks to estimate fold change in tumor
volume after injection (each dot or square represents an individual tumor). b,
Representative images of Hs578t xenograft tumors with control shRNA (top row) or
EHD2 shRNA (bottom row) from athymic mice at the experiment endpoint. Tumors
shown are representative of the median from each group.
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Figure 3.20. EHD2 shRNA-mediated knockdown alters tumor cell morphology and
reduces proliferation of TNBC cells in vivo. a, Representative images of H&E staining
of xenograft tumor sections from HS578t cells with control or EHD2 shRNA to
demonstrate tumor cell morphology. b, Representative images (20x magnification) of
Ki67 staining of xenograft tumor sections from HS578t cells with control or EHD2
shRNA.
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Figure 3.21. Validation of EHD2 shRNA-mediated knockdown in TNBC cells in vivo.
a, Representative images of xenograft tumor sections from HS578t cells with control or
EHD2 shRNA stained with anti-EHD2 (red) and DAPI (blue). Scale bars represent 200
µm.
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Figure 3.22. EHD2-shRNA mediated knockdown reduces metastatic potential of
TNBC cells in vivo. a, Representative images of primary xenograft tumors and lungs
from mice injected with 5 x 106 MDA-MB-231 cells with control or EHD2 shRNA.
Tumors and lungs were harvested 13 weeks after injection of MDA-MB-231 cells. Lung
metastases were visually counted for each group.
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Figure 3.23. EHD2 knockdown reduces invasive growth of MDA-MB-231 cells in
Matrigel culture. a, MDA-MB-231 cells were plated as single cells in 100% Matrigel and
allowed to grow for 7 days in culture. Cell invasion through Matrigel was imaged at day
7. Scale bar represents 1000 µm. Magnified image scale bar represents 200 µm. b, The
percentage of invasive spheroids per field was quantified for MDA-MB-231 cells with
control or EHD2 shRNA (Each dot represents a field, *** indicates p<0.001).
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Figure 3.24. EHD2 knockdown reduces invasive growth of BT549 cells in Matrigel
culture. a, BT549 cells were plated as single cells in 100% Matrigel and allowed to grow
for 7 days in culture. Cell invasion through Matrigel was imaged at day 7. Scale bar
represents 1000 µm. Magnified image scale bar represents 200 µm. b, The percentage of
invasive spheroids per field was quantified for BT549 cells with control or EHD2 shRNA
(Each dot represents a field, *** indicates p<0.001).
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Figure 3.25. EHD2 knockdown reduces TNBC cell membrane repair ability in vitro. a,
TNBC cells with control or EHD2 shRNA were incubated with CascadeBlue-conjugated
dextran to label cells with damaged membranes via bulk membrane wounding from
glass bead rolling. Five minutes after wounding, cells were rinsed and incubated with
TRITC-conjugated dextran to label cells that failed to repair. Hs578t cells are shown as
representative for the effects of EHD2 knockdown on membrane repair. Scale bar
represents 200 µm. b, The number of wounded cells with repaired membranes were
compared to the number cells with failed membrane repair and represented as a
percentage for MDA-MB-231, BT549, and Hs578t cells. Quantification represents three
independent experiments. P<0.001 (***), p<0.0001 (****)
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III.4 Discussion
In this chapter, we have shown that EHD2 is a novel marker and important
regulator of membrane repair and tumorigenicity in triple-negative breast cancer. We
first demonstrated that EHD2 is exclusively expressed within the myoepithelial/basal
layer of the murine and human mammary duct. We used a newly developed EHD2-/mouse strain to validate our EHD2 antibody specificity and confirmed the exclusive
expression of EHD2 throughout the major timepoints of mammary gland development.
In accordance with its role as an essential regulator of caveolae dynamics, EHD2
localization in the mammary duct was consistent with the known expression pattern of
the caveolae structural proteins, caveolin-1 and caveolin-2 (Pinilla et al. 2006; Savage et
al. 2008). While EHD2 knockout in mice did not result in an obvious phenotype, we did
observe a distinct increase of EHD1 expression within the myoepithelial/basal layer of
the mammary duct. This suggests that EHD1 may serve a functionally redundant role to
EHD2 within these compartments. Interestingly, other tissues of EHD2-/- mice did not
exhibit similar increases in EHD1 expression (data not shown), and shRNA-mediated
knockdown of EHD2 in mammary epithelial cells and breast cancer cells did not elicit
increased EHD1 protein expression. This suggests that the observed increase of EHD1 in
EHD2-/- mice may be regulated via genomic mechanisms instead of through protein
expression levels. More research into this phenomenon would be interesting since the
members of the EHD family of proteins have many overlapping cellular functions
(George et al. 2007; Cai et al. 2013). Regardless, this compartment-specific redundancy
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role of EHDs has been observed previously in other EHD knockout mice (Sengupta et al.
2009; George et al. 2011).
Our findings in normal mammary gland tissue were paralleled by the expression
of EHD2 in breast cancer cell line subtypes. Most triple-negative breast cancers are often
referred to as basal-like breast cancer because they have a gene expression profile similar
to the myoepithelial/basal layer of the mammary duct (Savage et al. 2007; CharafeJauffret et al. 2006; Jacquemier et al. 2005; Neve et al. 2006; Chin et al. 2006). Our
initialing screening of 24 breast cancer cell lines demonstrated that EHD2 protein
expression levels were indeed present in basal-like cells and mostly absent in luminal
and HER2-positive breast cancer lines. These results were further validated by using a
publicly available breast cancer cell line expression database (Ringnér et al. 2011) based
on gene expression data and molecular subtype classifications that were previously
described (Neve et al. 2006). Moreover, EHD2 mRNA expression was positively
correlated with both caveolin-1 and caveolin-2 mRNA, and was primarily expressed
within the highly-metastatic basal B molecular subtype.
To expand our use of the publicly-available breast cancer gene expression
databases, we showed that EHD2 mRNA expression correlated with EHD2 protein
expression in a select set of breast cancer cell lines both in vitro and in vivo. Importantly,
we also presented the novel finding that EHD2 and caveolin-1 protein expression was
co-expressed and co-localized nearly perfect throughout our selected breast cancer cell
lines. The co-localization of caveolin-1 and EHD2 in TNBC cell lines was predominantly
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in the rear of motile cells in vitro. While the caveolin-1 localization was consistent with
what has been shown for other cell systems (Masuelli et al. 2012; H. Yang et al. 2016),
there was a fraction of EHD2 that was localized near the cell front and not co-localized
with caveolin-1. This suggests that EHD2 is serving a role at the leading edge of motile
TNBC cells that is independent of any regulatory roles involving caveolae. However,
this could also be a misinterpretation since caveolae can also exist in a flattened state
(Nassoy and Lamaze 2012; Senju and Suetsugu 2016) and the rear of the cell may simply
represent a more concentrated pool of caveolae. This question could be answered in the
future with additional imaging experiments using electron microscopy (Sinha et al.
2011).
Our findings also demonstrated that EHD2 mRNA was positively correlated
with caveolin-1 and caveolin-2 mRNA expression in human breast cancer samples.
While EHD2 mRNA expression was not associated with any significant difference in
survival probability across all breast tumor subtypes, we did find that high EHD2
mRNA expression was significantly associated with lower survival probability in
patients with basal tumors. Caveolin-1 and caveolin-2 mRNA expression analysis
yielded similar results, once again confirming the close association between EHD2 and
the structural proteins of caveolae in TNBC. It is important to note that we also observe
high EHD2 expression within the stromal compartment of the mammary gland, mainly
adipocytes and endothelial cells. This could skew EHD2 mRNA expression levels if the
samples weren’t dissected carefully or analyzed via a process such as laser capture
microdissection (Braakman et al. 2017). However, given the similar survival probability
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profiles of caveolin-1 and caveolin-2 and the fact that they are expressed in the same
stromal compartments as EHD2, we can assume that the results from the mRNA
expression database are an accurate representation of tumor expression. This is
supported by research indicating that low stromal caveolin-1 expression is associated
with a lower probability of survival in breast cancer (Qian et al. 2011; Goetz et al. 2011).
Therefore, we can presume that any lower probability of survival from high caveolin-1
mRNA expression stems from tumor expression rather than stromal expression.
We followed up our findings from the mRNA expression database by validating
EHD2 protein expression in TNBC in a well-annotated TMA of 840 breast cancer
samples. Interestingly, we found that EHD2 protein localization within tumor samples
influence survival probability and varied by subtype. Although cytoplasmic EHD2
expression was consistent with our mRNA data and associated with TNBC and lower
probability of survival, EHD2 expression in the nucleus was associated with luminal
subtypes of breast cancer and a higher probability of survival. This nuclear expression of
EHD2 could explain the discrepancies we observed regarding EHD2 mRNA expression
and survival probability. Specifically, nuclear expression of EHD2 could be the reason
why high EHD2 mRNA expression does not show a significant difference in survival
across all breast tumor subtypes. It is also possible that our observations of nuclear
EHD2 are simply an artifact of sample preparation through immunohistochemistry.
Future experiments to isolate cytoplasmic and nuclear fractions of breast cancer cells
could help validate our IHC findings. Still, EHD2 does have a nuclear localization
sequence and has been shown to traffic to the nucleus (Pekar et al. 2012; Bahl,
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Naslavsky, and Caplan 2015). While the function of EHD2 shuttling to the nucleus is
mostly unclear, our observations are the first time that differential nuclear and
cytoplasmic expression of EHD2 has been documented in cancer.
Disregarding nuclear expression, however, our TMA results did indicate a
significant association between cytoplasmic EHD2 and caveolin-2 expression. Although
caveolin-1 did not exhibit the same significant association, caveolin-1 and caveolin-2
were shown to be associated with TNBC in the same cohort of patient samples (Elsheikh
et al. 2008). The expression of EHD2, caveolin-1/2, and other basal-like markers in TNBC
could be a due to the cancer originating from the myoepithelial/basal layer or simply
part of a transcriptomic program that leads to a basal-like phenotype (Savage et al.
2008). Regardless, these findings demonstrate that EHD2 is a novel marker of TNBC and
an indicator of poor outcome, and may be serving an important regulatory role for
caveolae in TNBC.
Metastasis is the ultimate cause of death among the overwhelming majority of
breast cancer patients (Kast et al. 2015; Gerratana et al. 2015; Wu et al. 2016). Triplenegative breast cancer comprises only 10%- 15% of all breast cancer cases, yet it is
clinically challenging due to its highly metastatic nature (Marmé and Schneeweiss 2015;
Molnár et al. 2017). To expand upon our observational findings, we selected three cell
lines (MDA-MB-231, BT549, and HS578T) to test the functional effects of EHD2 shRNAmediated knockdown in TNBC. Our initial findings demonstrated that EHD2
knockdown resulted in decreased invasiveness and tumorigenicity of TNBC both in vitro
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and in vivo. EHD2 knockdown did not significantly affect proliferation, migration, or
morphology of TNBC cells in normal 2D culture conditions. However, we found that
EHD2 knockdown significantly reduced invasiveness and anchorage-independent
growth in vitro. These results conform with our observational findings but also suggest
that EHD2 could be regulating the tumorigenicity or viability of the cancer stem cell
population in TNBC. Interestingly, previous studies of EHD2 in breast cancer described
the opposite effect (X. Yang et al. 2015; Yuhua Shi et al. 2015). Briefly, EHD2 was
suggested to serve as a tumor suppressor since siRNA-mediated knockdown led to
enhanced migration and invasion in MDA-MB-231 and MCF7 cells. Our findings
suggest the contrary. Not only did our study utilize a well-annotated and 10-fold larger
cohort of breast cancer patient samples, but we also confirmed that the MCF7 cell line
lacks EHD2 expression through western blotting, immunofluorescence, and multiple
publicly available mRNA expression databases. Furthermore, we demonstrated that
EHD2 knockdown dramatically reduces tumor growth and metastasis in vivo using
MDA-MB-231, BT549, and HS578T orthotopic tumors. We also validated the specificity
of our EHD2-antibody through western blot and immunofluorescence analysis of cells
with EHD2 shRNA and tissue from EHD2-/- mice. These findings suggest that EHD2
plays a novel role as an indispensable regulator of tumorigenicity and metastatic
potential in TNBC.
In breast cancer, breast density and matrix-stiffness are associated with poorer
outcome (Wei et al. 2015; Provenzano et al. 2009). Breast cancer cells rely on mechanoprotective and membrane repair processes to maintain their high growth rate and to
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survive in hostile tumor microenvironments. Furthermore, caveolin-1, a required
structural component of caveolae, has recently been shown to be upregulated in TNBC
cells subjected to fluid shear stress, indicating that caveolae serve a mechanoprotective
role during breast cancer metastasis (H. Yang et al. 2016). Previous studies have
confirmed that EHD2-interacting proteins such as myoferlin localize to caveolae and
regulate membrane repair in TNBC and lung carcinomas (Turtoi et al. 2013; Leung et al.
2013). While caveolae and EHD2 have established roles in membrane repair (Doherty et
al. 2008; Marg et al. 2012; Schilling and Patel 2015; Yin Shi et al. 2015; Echarri and Del
Pozo 2015), little is known about the role of EHD2 in regulating caveolae-mediated
membrane repair. Although our orthotopic tumor model results showed that EHD2
knockdown decreased tumor growth, the tumors with EHD2 shRNA were still able to
grow to an extent. We found that the tumors with EHD2 shRNA grew at rate similar to
control shRNA tumors up to four weeks after implantation. After week four, the EHD2
shRNA tumors halted growth and maintained their volume until the end of the
experiment (11 – 13 weeks), indicating that the tumors were unable to maintain a larger
burden. Although we observed decreased proliferation in EHD2 shRNA tumors, we also
saw a dramatic loss of the stellate tumor cell morphology characteristic of MDA-MB-231,
BT549, and HS578T cell lines (Hughes et al. 2008; Nguyen-Ngoc et al. 2015). This
observation was repeated in vitro by 3D-culturing of TNBCs in Matrigel, indicating a
defect in the membrane protective processes required for TNBC invadopodia. Further
analysis confirmed that EHD2 regulates membrane repair in TNBC, consistent with its
established role in controlling caveolar dynamics and membrane repair in other models.
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Altogether, these findings suggest that EHD2 is serving a novel role as an essential
regulator of caveolar-mediated membrane-protective functions in TNBC.
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Chapter IV: Conclusions and Future
Directions
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IV.1 Conclusions
In summary, we used publicly available gene expression databases, clinical
breast cancer samples, and shRNA-mediated knockdown within in vitro and in vivo
breast cancer models to provide evidence that EHD2, a member of the EHD protein
family of endocytic recycling regulators, serves a novel and critical role in regulating
caveolar-mediated mechanisms of plasma membrane maintenance essential for tumor
growth and development in Triple-negative breast cancer.
Based on our studies, EHD2 is fundamentally important for triple-negative
breast cancer invasiveness and tumor growth. Moreover, EHD2 is a key regulator of
caveolae dynamics and interacts with proteins that regulate the caveolae-mediated
membrane repair and protection processes. These mechanoprotective functions of
caveolae allow TNBC cells to maintain their high growth rate, survive in the hostile
tumor microevironment, and metastasize. Given our observations that EHD2 is highly
expressed and critical for tumorigenesis in TNBC, as well as previous studies that have
solved the structure of EHD2 and found it to be an important regulator of caveolae
dynamics and stability through ATP binding, our findings here have uncovered a novel
function of EHD2 as regulator of caveolae-mediated mechanoprotection in cancer that
may be a potential therapy target for TNBC via specific inhibition of EHD2 ATPase
activity. Further exploration of other human cancers may show a broader role of EHD2
across human cancer pathogenesis.
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IV.2 Future Directions
In this thesis, we demonstrated the co-expression of and co-localization of EHD2
and caveolin-1 in triple-negative breast cancer. We also showed that EHD2 was
indispensable for plasma membrane repair and invasive spheroid formation in TNBC
cell lines. While this is consistent with the role of caveolae in membrane repair and role
of EHD2 in regulating caveolae, we still need to confirm that EHD2 is directly
influencing caveolar-mediated membrane repair processes. To accomplish task, future
studies will need to perform structure function analysis to determine which domains of
EHD2 are required for efficient plasma membrane repair. Transfection of EHD2 mutant
constructs into TNBC cells to recapitulate the membrane repair phenotype will help
establish which domains are essential for this process. While many EHD2 mutants have
been generated and discussed in the literature, the EHD2 mutant unable to bind ATP
(EHD2 T72A) has been shown to be unable to interact and regulate caveolae (Moren et
al. 2012; Stoeber et al. 2012). However, it would also be prudent to instigate the many
EHD2 interacting partners (myoferlin, pacsin 2, cavin 1, and cavin 2) that are also known
to be associated and/or important for caveolae formation and regulation. Additional
shRNA-mediated knockdown of caveolin-1 and caveolin-1 in TNBC cells would aslo
help confirm our hypothesis if knockdown is able to recapitulate our observed
phenotypes of defective membrane repair and reduced tumorigenicity.
Despite the clear association of EHD2 with triple-negative breast cancer, most
breast cancer samples and cell lines do not express EHD2. This is an interesting finding
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that needs to be examined further. Moreover, previous studies have shown that
membrane repair is essential to the invasiveness of these breast cancer cells lacking
EHD2, specifically the luminal subtype cell lines MCF7 (Jaiswal et al. 2014). The MCF7
cells were found to rely mostly on annexin and s100 protein mediated repair pathways,
indicating that caveolae-independent repair mechanisms are present in these cells, but it
would be crucial to investigate other luminal A, luminal B, and HER2+ cell lines. While
we show that caveolin-1 is primarily expressed in TNBC, some TNBC cell lines like
MDA-MB-468 do not express the protein or EHD2. These cells would also be important
to investigate. Moreover, although EHD2 is absent, we have shown that EHD1 and
EHD4 are highly expressed in luminal and most HER2+ cell lines. It would be prudent
to investigate the role of these EHDs in regard to plasma membrane repair.
Additionally, our lab has demonstrated that EHD1 is a critical component in the
trafficking and signaling of the receptor tyrosine kinase CSF1-R in macrophages (Cypher
et al. 2016). Given that HER2 is a receptor tyrosine kinase, it would interesting to
examine the effects of EHD1 shRNA-mediate knockdown within these cells. The same
experiments would be worthy of investigating within the EHD2-absent, TNBC cell lines
that are high in EGFR expression.
Finally, if the ATP-binding deficient mutant, EHD2 T72A, is able to recapitulate
the plasma membrane repair defects observed in TNBC cells with EHD2 knockdown,
development of an ATP-binding pocket specific inhibitor could provide enormous
therapeutic potential to TNBC patients in the future.
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Abstract:
Biochemical pathways whose rewiring is required for tumor progression
represent potential targets to devise new combinatorial therapies. CHIP/STUB1
ubiquitin ligase is a negative co-chaperone of HSP90/HSC70, and its expression is
reduced or lost in several cancers, including breast cancer. Using an extensive and wellannotated breast cancer tissue collection, we identified the loss of nuclear but not
cytoplasmic CHIP to predict more aggressive tumorigenesis and poorer patient survival,
with loss of CHIP in two-thirds of ErbB2+ and triple-negative breast cancers and in onethird of ER+ breast cancers. Reduced CHIP expression was seen in breast cancer patientderived xenograft tumors and in ErbB2+ and triple-negative breast cancer cell lines.
Ectopic CHIP expression in ErbB2+ lines suppressed in vitro oncogenic traits and in vivo
xenograft tumor growth. An unbiased screen for CHIP-regulated nuclear transcription
factors identified a number of candidates whose DNA-binding activity is up- or downregulated by CHIP. We validated Myeloid Zinc Finger 1 (MZF1) as a CHIP target as it
has emerged as a key positive regulator of cathepsin B/L (CTSB/L)-mediated tumor cell
invasion downstream of ErbB2. We show that CHIP negatively regulates CTSB/L
expression in ErbB2+ and other breast cancer cell lines. CTSB inhibition abrogates
invasion and matrix degradation in vitro and halts ErbB2+ breast cancer cell line
xenograft growth. We conclude that loss of CHIP remodels cellular transcriptome to
unleash critical pro-oncogenic pathways, such as the matrix-degrading enzymes of the
cathepsin family, whose components can provide new therapeutic opportunities in
breast and other cancers with loss of CHIP expression.
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Introduction
The ubiquitin-proteasome system (UPS) plays diverse roles in normal cellular
homeostasis. Ubiquitination cascade involves two ubiquitin-activating (E1) enzymes, a
small group of ubiquitin-conjugating (E2) enzymes and a large repertoire of ubiquitin
ligase (E3) enzymes. E3s dictate substrate specificity and comprise two broad groups:
the human papilloma virus E6-interacting (HECT) domain and the really interesting
new gene (RING) finger domain protein families (1).
Consistent with roles of the UPS as a contributor to oncogenesis, certain cancers,
e.g., multiple myeloma, are clinically treated with proteasome inhibitors (1). Recent
focus has shifted to substrate-specific elements of the UPS, such as E3s, with MDM2
inhibitors currently in clinical trials for several malignancies (clinicaltrials.gov). Notably,
mutations of E3s, such as CBL (2) or FBW7 (3) convert them into oncogenes.
The C-terminus of HSC70-Interacting Protein (CHIP)/STIP1 homology and UBox containing protein 1 (STUB1) is a U-box subfamily RING finger type E3 that
regulates protein quality control as a negative co-chaperone of the HSP90/HSC70
chaperone by targeting unfolded or misfolded proteins for proteasomal degradation (49). CHIP-null mice exhibit strain-dependent embryonic lethality and hyper-sensitivity to
stresses (10). CHIP also targets many mature proteins for ubiquitination and
proteasomal degradation or degradation-independent regulation (11).
CHIP targeting of oncogenic driver/co-drivers, such as ErbB2, has prompted
analyses of CHIP expression in human tumors. Analysis of matched normal and tumor
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tissues from 27 breast cancer patients revealed progressive loss of CHIP mRNA
expression with tumor progression; CHIP knockdown in CHIP-high MCF-7 (ER+) cells
increased and CHIP overexpression in CHIP-low MDA-MB231 (triple-negative; TN)
cells suppressed oncogenic traits in vitro and xenograft tumor growth and metastasis in
vivo (12). Another study of 33 normal and 127 breast tumor samples also showed an
inverse relation of CHIP mRNA levels with increasing grade and Nottingham
Prognostic Index (13). A third study of 183 patient found an inverse correlation between
ErbB2 and CHIP protein levels, with reduced CHIP expression associated with tumor
progression (14). Thus, CHIP appears to function as a suppressor of breast cancer
tumorigenesis. However, the extent of loss of CHIP expression in breast cancer subtypes
is unknown.
Mechanistically, CHIP can target cell surface, cytoplasmic, nuclear or secreted
proteins for ubiquitin-dependent degradation (11). Relevant to breast cancer, CHIP
targets ERB2 (15-17), SRC-3 transcriptional coactivator (12), macrophage inhibitory
factor (18), protein kinase 6/breast tumor kinase (19) and actin regulatory protein
profilin-1 (20). However, how loss of CHIP promotes oncogenesis remains unclear.
Here, we assessed both nuclear and cytoplasmic CHIP expression in a wellannotated cohort of >900 breast cancer specimens. We show that a majority of ERBB2+
and TN, and a minority (but numerically large number) of ER+ breast cancers show loss
of CHIP expression, and that loss of the nuclear and not the cytoplasmic CHIP
expression predicts features of tumor progression and invasion, and poor patient
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survival. Loss of CHIP expression in ERBB2+ breast tumor cell lines unleashes a
program of increased tumor cell invasion and migration in vitro and tumorigenesis in
vivo, as reported with a TN cell line model (12). Given the importance of the loss of
nuclear CHIP, we performed an unbiased screen of the impact of low vs. high CHIP
levels on DNA-binding activities of cellular transcription factors in ERBB2+ and TN
breast cancer cell lines and identified a number of shared CHIP-regulated transcription
factors. Here, we focus on CHIP regulation of MZF1 as it was recently identified as a key
mediator of pro-invasive signaling downstream of ERBB2 through upregulation of the
expression of matrix degrading cathepsin B and L enzymes (21). We show the CHIP
dependence of this pathway in cell lines representing various breast cancer subtypes
and demonstrate that chemical targeting of CTSB inhibits ERBB2-driven tumorigenesis.
We conclude that loss of CHIP expression unleashes a MZF1-dependent and CTSB/Lmediated pro-oncogenic pathway in breast cancer.
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Materials and Methods
Details methods are presented in Supplementary Methods.
Cell culture: ErbB2-overexpressing breast cancer cell lines SKBR3 and BT474 (ATCC)
were cultured in complete α-MEM medium with 5% fetal bovine serum, 10 mM HEPES,
1 mM each of sodium pyruvate, nonessential amino acids and L-glutamine, 50 µM 2ME, and 1% penicillin/ streptomycin (Life technologies, Carlsbad, CA). ErbB2overexpressing breast cancer cell line 21MT1 (22) was cultured α-MEM medium
supplemented as above and with 1 μg/mL hydrocortisone and 12.5 ng/mL epidermal
growth factor (Sigma-Aldrich, St. Louis, MO). The lentiviral packaging cell line TSA-54
(23), the ER+ breast cancer cell line MCF7 and the ErbB2-negative and estrogen
receptor/progesterone receptor-negative (TN) breast cancer cell line MDA-MB-231
(ATCC) were cultured in DMEM medium (Life technologies) and supplements as for
BT474. For retroviral overexpression of Myc-tagged human CHIP (16), HEK-293T cells
were transfected with pMSCV-CHIP and packaging vectors, and supernatants used to
infect ErbB2+ breast cancer cell lines followed by selection in puromycin. Cell lines were
regularly tested for mycoplasma. Cell lines were not continuously cultured for >3
months.
Antibodies and Reagents: Rabbit anti-CHIP antibody used for blotting has been
described (16). Other primary antibodies or secondary conjugates for fluorescence or
immunoblotting analyses are described under Supplementary Methods.
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Cell lysis, immunoprecipitation and immunoblotting: Cells lysates were prepared in
RIPA or Triton X-100 lysis buffers (as indicated in figure legends) and used for
immunoprecipitation and immunoblotting analyses as described in Supplementary
Methods.
Quantitative real-time PCR: Total RNA extracted using TRIzol reagent (Invitrogen) and
reverse transcribed using Quantitative real-time PCR kit (cat. 204141, Qiagen,
Germantown, MD) was used for real-time QPCR with primers described in
Supplementary Methods.
Cell growth assays: Cell growth was analyzed as cumulative proliferation over 5 serial
weekly passages and by soft agar anchorage-independent growth assay as described
under Supplementary Methods.
Transwell migration and invasion assays: The migration or invasion of cells was
analyzed using uncoated or Matrigel-coated Transwell chambers as described under
Supplementary Methods.
Extracellular matrix (ECM) degradation assay: This assay was carried out using QCM™
Gelatin Invadopodia kit (Cat. ECM670, EMD Millipore, Billerica, MA) according to the
manufacturer’s protocol. Details are presented in Supplementary Methods. ECM
degradation, seen as focal loss of fluorescent signal (“holes”) in the labeled gelatin layer
was quantified using Image J (NIH).
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Xenograft tumorigenesis: 106 cells in Matrigel (BD Biosciences) were implanted in the
mammary fat pad of female NSG mice (The Jackson Laboratory) primed with s/c
estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research of America, Sarasota, FL)
and tumor growth monitored weekly for 10 weeks. After euthanasia, tumors were
imaged, and formalin-fixed and paraffin-embedded for further analyses. Details are
presented in Supplementary Methods.
Protein/DNA array: A protein/DNA combo-array kit (Cat. MA1215, Affymetrix, Santa
Clara, CA) was used to simultaneously screen 345 transcription factors for DNA-binding
activity per vendor protocol with signals detected using chemiluminescence (See
Extended Methods).
Electrophoretic mobility shift assay (EMSA): EMSA was carried out using an EMSA kit
(cat. 20148, Life Technologies, Waltham, MA) as described in Extended Methods.
Cathepsin B (CTSB)/Cathepsin L (CTSL) activity assay: CTSB/L activity was assayed
using the Magic Red CTSB/L Activity Kit (Cat. 937 & 941, Immunochemistry
Technologies, Bloomington, MN) according to the manufacturer’s protocol (See
Extended Methods). Experiments were run in triplicates and repeated thrice. Ten
random fields per well were imaged and the fluorescence intensity was quantified using
Image J (NIH).
Human and animal subjects: The use of human tissues was approved by the Ethics
Committee of the University of Nottingham. Mouse studies were pre-approved by the
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UNMC Institutional Review Board (IRB) Committee, in compliance with Federal and
State guidelines.
IHC analysis of breast cancer tissue microarrays: Tissue microarrays (TMAs)
corresponding to a well-annotated 971 breast cancer patient cohort at the University of
Nottingham Hospital Breast Unit and a commercial TMA (BR20837, from US Biomax,
INC.) were analyzed by IHC staining (see Extended Methods for details) with a
previously described (27) anti-rabbit CHIP antibody that was further validated
(Supplementary Figure 1).
Semi-quantitative assessment of staining intensity utilized a modified
histochemical score (H-score) ranging from 0 to 300 based on multiplying staining
intensity of 0 to 3 (negative, 0); weak, 1; moderate, 2; strong, 3) by the percentage of
positive cells (See Extended Methods. Nuclear expression of >1 or cytoplasmic
expression of >110 was considered positive (See Extended Methods). The IHC staining
results were statistically analyzed using the SPSS 16.0 statistical software (SPSS Inc.,
Chicago, IL, USA) (See Extended Methods).
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Results
Reduced nuclear CHIP expression in breast cancer correlates with tumor progression,
invasion and poorer patient survival
As small previous studies (12-14) have not clarified which breast cancer subtypes
lose CHIP expression, we performed immunohistochemistry (IHC) analysis of formalinfixed and paraffin-embedded tissue microarrays (TMAs) from a well-annotated cohort
of 971 breast cancer patients (Supplementary Table 1) (24-28) using an established rabbit
anti-CHIP antibody (16) further validated in western blotting with lysates of CHIPdepleted or ectopic CHIP-expressing cell lines (Supplementary Figure S1). Initial IHC of
a commercial breast cancer TMA (208 samples) detected both cytoplasmic and nuclear
CHIP within tumor cells and in surrounding normal epithelium (Figure 1A). In the 971sample TMA, 423 and 314 samples, respectively, were evaluable for cytoplasmic and
nuclear staining, with multiple staining patterns: low cytoplasmic/low nuclear, low
cytoplasmic/high nuclear, high cytoplasmic/low nuclear; or high cytoplasmic/high
nuclear (Figure 1B; Supplementary Table1). Loss of nuclear CHIP staining showed a
significant positive correlation with biochemical markers of tumor progression and
metastasis, reduced ER and PR staining, altered cytokeratins (CK 18, CK19), increased
expression of early epithelial-mesenchymal transition markers (N-cadherin, P-cadherin)
and expression of EGFR family proteins (EGFR, ErbB2, ErbB4) (Supplementary Table 2).
Only CK 18 (p=0.001) and ErbB2 (p=0.016) expression correlated with reduced
cytoplasmic CHIP staining (Supplementary Table 2). Lower nuclear but not cytoplasmic
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CHIP staining showed a significant positive correlation with clinical-pathological
features of tumor progression (higher tumor size, tumor grade, pleomorphism and
mitotic status) (Supplementary Table 1). Using the previously-established ER, PR and
ErbB2/Her2 expression status of the TMA samples (25-29), low CHIP expression was
seen in two-thirds of ErbB2+ and TN cases and about one-third of ER+ cases. KaplanMeier analysis revealed that low nuclear but not the cytoplasmic staining pattern
correlated significantly with poorer breast cancer-specific survival (Nuclear CHIP,
p=0.003 Vs. cytoplasmic CHIP, p=0.469; Figure 1C).

CHIP suppresses tumorigenic traits in ErbB2+ breast cancer cell lines
Validating IHC results, a majority of cell lines representing the ErbB2+ and TN
breast cancer subtypes showed lower CHIP mRNA and protein levels compared to ER+
lines (Supplementary Figure 2A and 2B); the ER+ and TN cell line results confirm a
previous report (12). Western blotting of 12 breast cancer patient-derived xenograft (29)
lysates confirmed the lower or absent CHIP expression in TN, ErbB2+ and some ER+
breast cancers (Supplementary Figure 2C). The CHIP expression status in the
commercial TMA was consistent with these results (Supplementary Figure 2D).
To gain mechanistic insights into how the loss of nuclear CHIP promotes
oncogenic progression, we utilized ErbB2+ breast cancer cell lines (BT474, SK-BR3 and
21-MT1) as primary models, confirming key findings in TN (MDA-MB231) and ER+
(MCF-7) lines. We engineered 3 ErbB2+ lines and MDA-MB231 cells to stably
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overexpress Myc-CHIP (CHIP-hi lines) (or vector control; CHIP-lo lines) and MCF-7
cells with CHIP shRNA (CHIP-lo) to deplete the endogenous CHIP expression (or a
control shRNA; CHIP-hi) (Supplementary Figure 1). As CHIP expression in MDA-MB231 cells is known to suppress oncogenic attributes (12), these served as controls.
While no significant differences in cell proliferation were observed over a single
passage, confirming previous MDA-MB231 results (12), cumulative cell proliferation
over multiple passages was modestly but significantly lower in CHIP-hi vs. control cells
(Figure 2A). CHIP-high cells exhibited a significantly lower number of colonies in soft
agar compared to control cells (Figure 2B). CHIP-hi cells exhibited significantly reduced
Transwell migration (Figure 2C). Finally, CHIP-hi 21MT1 cells exhibited significantly
reduced invasion through Matrigel compared to CHIP-lo control cells (Figure 2D).
Analysis of CHIP-lo vs. CHIP-hi MDA-MB231 cells, as controls, confirmed the
expected reduction in primary tumor growth and lung metastasis upon CHIP
overexpression (12) (Supplementary Figure 3). Notably, the CHIP-hi BT474 cells formed
significantly smaller xenograft tumors compared to those with CHIP-lo cells (Figure 3A
and 3B). Exogenous CHIP overexpression in tumors was confirmed by western blotting
(Figure 3C). Histologically, the CHIP-hi BT474 tumors showed lower nuclear atypia and
mitotic index (Figure 3D), and reduced Ki67+ proliferating cells (Figure 3E and 3F)
compared to CHIP-lo BT474 tumors. No significant difference in immunostaining for the
apoptotic marker cleaved-caspase 3 was noted (Figure 3E and 3G), suggesting a
primarily cytostatic impact of CHIP overexpression. These studies support the tumor
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suppressor role of CHIP in ErbB2+ breast cancer as suggested by our clinicalpathological analyses.

Identification of nuclear targets of CHIP in breast cancer
As loss of nuclear but not cytoplasmic CHIP expression predicted tumor
progression and poor patient outcomes, we assessed the cognate DNA-binding activities
of 345 cellular transcription factors in nuclear extracts of control vs. CHIP-hi ErbB2+
BT474 cells, using a commercially-available array platform, expressing the DNA-binding
activity in CHIP-hi over CHIP-lo extracts as a fold ratio. Subsets of transcription factors
showed changes in DNA-binding activities outside of the arbitrary 3-fold cut-off,
representing potential direct or indirect targets of negative or positive regulation by
CHIP (Figure 4A, left). These (Supplementary Table 3) included known CHIP targets,
such as p53 and NFkB (30, 31) validating the approach. Analysis of CHIP-hi vs. CHIP-lo
(control) MDA-MB231 cells (Fig 4A, right) showed that most CHIP targets were shared
with the BT474 cell model (see Supplementary Table 4) (Fig 4A), although the extent of
changes differed. Thus, our unbiased screen identified novel CHIP-targeted
transcription factors whose deregulated function upon loss of CHIP expression may
contribute to tumor progression.
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MZF1 is a direct target of CHIP-mediated ubiquitination and degradation
We focused further on myeloid zinc finger 1 (MZF1), whose DNA-binding
activity was down-regulated in CHIP-hi BT474 and MDA-MB231 cells (Figure 4A and
6A; MZF1 highlighted in red), as it was recently identified as a nexus of ErbB2 signaling
that culminates in tumor cell invasiveness through increased transcription of matrixdegrading enzymes cathepsin B (CTSB) and L (CTSL) (21). Electrophoresis mobility shift
assay (EMSA) using sequences corresponding to MZF1 binding sites on the CD34 gene
promoter (32) confirmed reduced binding activity (shifted bands) in CHIP-hi vs. CHIPlo BT474 cells (Figure 4B). The MZF1 mRNA level was reduced in CHIP-hi vs. CHIP-lo
cells BT474 cells (Figure 4C), suggesting the regulation of upstream modulators of MZF1
transcription as part of CHIP-dependent reduction in DNA-binding activity. MZF1
protein level was reduced in CHIP-hi vs. CHIP-lo cells, and anti-ubiquitin blotting of
MZF1 immunoprecipitations showed increased MZF1 ubiquitination in CHIP-hi vs
CHIP-lo BT474 cells (Figure 4D). Co-transfection of CHIP and MZF1 in HEK-293T cells
revealed CHIP dose-dependent MZF1 ubiquitination (Figure 4E, upper) and reduction
in protein level (Figure 4E, bottom). These results support the conclusion that MZF1 is a
bona-fide target of CHIP, involving indirect transcriptional downregulation and CHIPdependent ubiquitination and degradation of MZF1.
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CHIP is a negative regulator of MZF1-dependent and Cathepsin B/L-mediated ECM
degradation
CTSB/L are key regulators of tumor invasion, angiogenesis and metastasis (33),
and their MZF1-dependent transcriptional upregulation was shown to mediate in vitro
tumor cell invasion upon ErbB2 overexpression in breast cancer cells (21). We therefore
asked if CHIP regulation of MZF1 translates into control of CTSB/L expression. EMSA
with a DNA probe from a known MZF1-binding site in the CTSB promoter (32)
confirmed reduced DNA-binding activity in the nuclear extracts of CHIP-hi vs. control
ErbB2+ cells (Figure 5A), with reduced CTSB and CTSL mRNA and protein levels
(Figure 5B and 5C), reduced CTSB/L enzymatic activities (Figure 5D-F) measured with a
fluorescent substrate (34), and reduced FITC-labeled gelatin degradation (35, 36) (Figure
5G and 5H). Thus, the MZF1/CTSB/L pro-invasion signaling axis is negatively regulated
by CHIP in ErbB2+ breast cancer cells.
Consistent with CHIP-dependent reduction in the DNA-binding activity of
MZF1 in CHIP-hi vs. CHIP-lo MDA-MB231 cells (Figure 4A), reduced mRNA and
protein levels of CTSB/L (Figure 6A and 6B), reduced CTSB/L activity (Figure 6C, 6D
and 6E) and reduced florescent gelatin degradation (Figure 6F and 6G) were observed in
CHIP-hi vs. CHIP-lo MDA-MB231 cells. Increased CTSB expression was also seen in
CHIP KD vs. control MCF7 cells (Supplementary Figure 4). Treatment of CHIP-lo
21MT1 cells (high CTSB/L activity; Figure 6D and 6E) with CA074, a specific inhibitor of
CTSB (37), abrogated fluorescent gelatin degradation, and markedly inhibited the
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transwell invasion of 21MT1 (Figure 7A-C) and MDA-MB-231 (7D-F) breast cancer cell
lines. Thus, we conclude that loss of CHIP expression across breast cancer subtypes
upregulates the pro-invasive MZF1-CTSB/L signaling axis.
To assess if the upregulation of CTSB expression and activity as a result of CHIP
downregulation contributes to oncogenesis in vivo, we grew BT474 xenograft tumors to
an average of 0.5 mm3 and treated the mice with CA074 (25 mg/Kg body weight, i.p.),
Trastuzumab (4 mg/Kg, tail vein injection) as a standard ErbB2-targeted therapeutic or
the vehicle control, based on previously used dosages (37-39). CA074 treatment led to a
marked and statistically-significant inhibition of tumor growth at multiple time points,
comparable to that seen with Trastuzumab (Figure 7G), supporting the conclusion that
one mechanism by which loss of CHIP promotes breast tumor progression is by
eliminating the negative regulation of MZF1 and unleashing the cathepsin expression.
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Discussion
Loss of expression of the HSP90/HSC70 co-chaperone CHIP E3 has emerged as a
mechanism to promote tumor progression. Here, we demonstrate that loss of nuclear,
and not cytoplasmic, CHIP expression is associated with tumor progression and shorter
survival in breast cancer patients, and is a feature of about two-thirds of ErbB2+ and TN
as well as a third of ER+ breast cancers. Importantly, we identify loss of CHIP as a key
mechanism to alter the DNA-binding activities of a substantial subset of cellular
transcription factors, and establish that loss of CHIP expression unleashes a pro-invasion
signaling cascade in which the CHIP target MZF1 promotes cathepsin B and L
expression. Using a chemical inhibitor strategy, we show that upregulation of MZF1CTSB axis due to loss of CHIP expression contributes to tumorigenesis.
IHC analyses of an extensive collection of well-annotated breast cancer TMAs
demonstrated that loss of nuclear CHIP signals correlates with markers of advanced
tumor progression, including higher tumor grade, mitotic index and markers of early
EMT (Supplementary Table 1), and significantly shorter breast cancer-specific and
progression-free survival (Figure 1C). Loss of nuclear CHIP was a feature of nearly twothirds of ErB2+ and TN subtypes, consistent with their poorer intrinsic patient outcomes
and higher metastatic odds (40, 41), and about a third of ER+ breast cancers
(Supplementary Table 2). In contrast, loss of cytoplasmic CHIP expression was only
associated with ErbB2 positivity, and did not predict poor patient survival (Fig 1C).
These results materially extend previous findings using smaller patient cohorts (12-14),
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and highlight the subtype preference of CHIP loss and the importance of the loss of
nuclear CHIP as a pro-oncogenic adaptation in breast cancer. Of note, the CHIP-low ER+
patients numerically exceed the CHIP-lo ErbB2+ and TN patients, and further studies
are needed to assess if these patients belong to a particular molecular sub-class.
Analyses in breast cancer cell lines confirmed the predominant loss of CHIP
expression in the ErbB2+ and TN subtypes. Using matched pairs of ErbB2+ breast cancer
cell lines with low endogenous CHIP expression vs. their CHIP-hi derivatives in
functional assays, we show that CHIP levels are a key determinant of ErbB2-driven cell
growth and invasiveness in vitro and xenograft tumor growth in nude mice, extending
previous findings using CHIP-reconstituted MDA-MB231 (TN) and CHIP-depleted
MCF-7 (ER+) lines (12), which served as controls. While we confirmed the lack of impact
of CHIP restoration on cell proliferation in a single passage (12), analyses over multiple
passages revealed a subtle but significant proliferative disadvantage (Figure 2A), which
is profound under anchorage-independent conditions (Figure 2B). Thus, CHIP serves as
a tumor suppressor for ErbB2+, TN and a proportion of ER+ breast cancers.
Furthering our novel findings that loss of nuclear and not cytoplasmic CHIP
correlates with tumor progression, an unbiased protein/DNA array screen identified a
number of transcription factors whose DNA-binding activities are directly or indirectly
up- or down-regulated by CHIP (Figure 4A), vastly expanding the list of potential
targets of CHIP in the context of cancer (30, 31). Here, we have focused on MZF1, whose
activity was downregulated by CHIP, since it was recently identified as a major
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transcriptional activator of CTSB/L-mediated tumor cell invasion downstream of ErbB2
in breast cancer cells (42). CTSB/L are overexpressed in primary breast cancers and CTSB
or MZF1 knockdown abrogated breast cancer cell invasiveness in vitro (42). Our EMSA
analyses confirmed the reduced MZF1DNA-binding activity in CHIP-hi breast cancer
cells (Figure 4B), and we show that MZF1 is both a direct target of CHIP for
ubiquitination and destabilization (Figure 4D) and also indirectly regulated at the
mRNA level, potentially due to CHIP regulation of upstream regulators of MZF1
expression such as MYC (43) (Figure 4A). Since intermediary kinases (CDC42BPβ, ERK2,
PAK4, PKCα) were implicated in MZF1-mediated CTSB/L transcription downstream of
ErbB2 (42), negative regulation of these kinases or ErbB2 (15, 16) may also contribute to
CHIP regulation of MZF1.
Our analyses support a key role of loss of CHIP as a mechanism to unleash the
MZF1-dependent transcriptional network that controls CTSB/L expression (Figure 5A)
and extracellular matrix (ECM) degradation (Figure 5G), and to promote oncogenesis
(Figure 2). CTSB is a well-established downstream mediator of invasive/metastatic
signaling in various cancers (44, 45), including breast cancer (21, 37). Specific CTSB
inhibition with CA074 reduced the matrix degradation and cell invasion in vitro and
tumor growth in vivo (Figure 6), providing further support for loss of CHIP expression
as a key breast cancer adaptation to unleash the pro-oncogenic MZF1-CTSB pathway.
The strong effect of CTSB inhibition alone on matrix degradation and xenograft tumor
growth, the latter comparable to Trastuzumab (Figure 7D), suggests that CTSB may be
the dominant player in BT474 cells, consistent with strong reported impact of CTSB
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depletion on in vitro invasiveness of ErbB2+ breast cancer cell lines (42). However,
further studies to assess the contribution of CTSL and other potential targets of MZF1
are warranted. Our in vitro results in TN and ER+ cell lines (Figure 4) also support the
unleashing of MZF1-CTSB/L pathway in the corresponding breast cancer subtypes, and
further studies in these and other tumors with loss of CHIP expression (11) will be of
interest.
In conclusion, our studies demonstrate that upregulation of MZF1/CTSB/L axis is
an important pro-oncogenic mechanism unleashed by loss of CHIP expression in breast
cancer. Given the established roles of cathepsins in matrix remodeling, invasion,
angiogenesis and metastasis (44, 45), future studies to establish the role and targeting of
MZF1-CTSB/L axis in metastatic tumor settings may provide new therapeutic
opportunities for breast and other tumors with loss of CHIP expression (31, 46-49).
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Figure 1. Reduced nuclear CHIP staining in primary breast cancer tissue microarrays
(TMAs) specimens. (A) Anti-CHIP IHC staining of a representative breast cancer
specimen vs. normal breast tissue to show cytoplasmic and nuclear staining. B.
Representative IHC staining patterns of loss of nuclear vs. cytoplasmic CHIP expression
in breast cancer TMAs. (C) Kaplan-Meier analysis of the correlation of breast cancerspecific survival (BCSS) with reduction in nuclear (left) or cytoplasmic (right) CHIP
expression. Number of patients and p values are indicated.
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Figure 2. Suppression of in vitro oncogenic attributes of CHIP-lo ErbB2+ breast cancer
cell lines upon CHIP overexpression. (A) Cumulative proliferation of CHIP-lo control
(MSCV-puro) vs. CHIP-hi (MSCV-CHIP) 21MT1, BT474 and SKBR3 cell lines. (B)
Anchorage-independent cell growth in soft agar after 3 weeks of culture. Y-axis, number
of colonies per 2500 cells. (C) Transwell migration assay. Y-axis, number of migrated
cells per high power field (HPF). D. Transwell Matrigel-invasion assay. Y-axis, number
of migrated cells per HPF. Data are mean +/- SEM of 3 experiments, each in triplicates.
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Figure 3. Reduced xenograft growth of CHIP-overexpressing BT474 cells in nude
mice. (A) Tumor volume of CHIP-lo (MSCV-puro) control and CHIP-hi (MSCV-CHIP)
BT474 xenografts over time N = 6 per group. *, p <0.05. (B) Photograph of resected CHIPlo (upper) and CHIP-hi (lower) BT474 cells. (C) Western blotting of endogenous and
overexpressed (Myc-tagged) CHIP in resected BT474 xenografts; HSC70, loading
control. (D & E) Representative H&E staining (D) or Ki67 (brown) plus cleaved caspase 3
(CC3; red) staining of CHIP-lo (left) and CHIP-hi (right) BT474 xenograft tumor sections.
(F, G) Quantification of Ki67 (F) and CC3 (G) positive cells in Figure E. Mean +/- SD, n=6.
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Figure 4. Identification of MZF1 as a CHIP-regulated transcription factor in ErbB2+
breast cancer cells. (A) DNA-binding activities of 345 transcription factors were
analyzed in CHIP-lo (MSCV-puro control) vs. CHIP-hi (MSCV-CHIP) BT474 and MDAMB-231cell lines. Y-axis, log-fold binding in CHIP-hi over CHIP-lo cells. The 3-fold
increase (upper) or decrease (lower) in binding (dotted lines) was used as cut-off. MZF1
(Open symbol). (B) Biotin-labeled MZF1-specific DNA sequences was used as to probe
nuclear extracts of CHIP-hi (MSCV-CHIP, C) vs. CHIP-lo (MSCV-puro, P) BT474 cells.
200-fold excess of non-labeled probe served as competitor. (C) Real-time qPCR analysis
of MZF1 mRNA levels in CHIP-hi vs. CHIP-lo BT474 cells. (D) Immunoblotting of MZF1
protein levels in CHIP-hi vs. CHIP-lo BT474 cells. (E) CHIP-dependent ubiquitination
and degradation of MZF1. Anti-MZF1 immunoprecipitations from lysates of HEK-293T
cells transfected with GFP- MZF1 +/- Myc- CHIP (0.5 or 4 g) w ere im m u n oblotted for
ubiquitin or MZF1 (upper panel), and whole cell lysates (lower panel) for MZF1, CHIP
or HSC70 (loading control).

177

178
Figure 5. CHIP levels control the expression of MZF1 target genes cathepsins B and L.
(A) EMSA analysis with CTSB promoter sequences in CHIP-hi vs. CHIP-lo BT474 cells
was done as in Figure 4B. (B) CTSB/L mRNA expression in CHIP-hi vs. CHIP-lo BT474
cells was analyzed by real-time qPCR. (C) Immunoblotting for CTSB/L protein levels in
CHIP-hi vs. CHIP-lo BT474 cells. (D) CTSB/L activities in CHIP-hi vs. CHIP-lo 21MT1
cells analyzed by the production of a red fluorescent cleavage product. (E, F)
Quantification of CTSB (E) and CTSL (F) activities presented in D. Mean+/- S.D., n=10.
(G) Degradation of FITC-labeled gelatin matrix (seen as black holes) by CHIP-lo vs.
CHIP-hi 21MT1 cells seeded for 48 hours and stained for actin-containing invadopodia
with phalloidin (red) and nuclei with DAPI (blue). (H) Quantification of gelatin
degradation presented in G. Mean +/- SD., n=4.
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Figure 6. The CHIP-MZF1-CTSB axis also operates in triple-negative breast cancer
cells. (A & B) CHIP-hi vs. CHIP-lo MDA-MB231 cells were analyzed by qPCR for
CTSB/L mRNA (A) and immunoblotting for protein expression (B). (C) CTSB/L activity
in CHIP-hi vs. CHIP-lo (MDA-MB231 cells analyzed as in Figure 4A. (D, E)
Quantification of CTSB (D) and CTSL (E) activity shown in Figure D. Mean+ S.D., n=10.
(F) FITC-gelatin degradation (black holes) in CHIP-hi vs. CHIP-lo MDA-MB231 cells. (G)
Quantification of FITC-gelatin degradation. Mean +/- SD., n=6.
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Figure 7. CTSB inhibition reduces ErbB2+ breast cancer cell tumorigenesis. (A) 21MT1
cells cultured on FITC-gelatin were treated with DMSO or CTSB inhibitor (CA074; 25
g/m l) for 48h an d d egrad ation an alyzed as in Figu re 5G. (B) Q u an tification of FITCgelatin degradation shown in 7A. Mean + S.D., n=4. (C) 21MT1 cells seeded on Matrigelcoated membranes were treated with DMSO (control) or CA074 (25 g/m l) for 24h ,
invaded cells stained with a fluorescent dye and quantified using a fluorescence reader.
Mean + S.D., n=18. (D) FITC-gelatin degradation by MDA-MB-231 cells was analyzed
after 48h culture in DMSO (control) or CTSB inhibitor (CA074; 25ug/ml) as in Figure 5G.
(E) Quantification of FITC-gelatin degradation. Mean + S.D., n=4. (F) Invasion of MDAMB-231 cells incubated with DMSO (control) or CA074 (25 /m l) as inFig. 6C. Mean +
S.D., n=8. (G) Groups of nude mice carrying BT474 xenografts (average 0.5 cm3 size)
received Trastuzumab (via tail vein; 4 mg/kg every 4 days) CA074 (i.p., 25 mg/kg in
saline daily) or saline (control), and tumor volumes were monitored every other day.
Mean +/- SEM., n=9.
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Tables:
Table 1: The association between Nuclear (N) CHIP and clinical-pathological
variables in the whole patient cohort.
Clinicopathological
variables

N-CHIP
Negative/ low
expression, N (%)

High expression, N
(%)

p-value

<50

231(35.1%)

100(31.8%)

0.316

>50

426(64.9%)

214(68.2%)

Pre

248(37.8%)

121(38.7%)

Post

409(62.2%)

192(61.3%)

<2 CM

89(44.5%)

168(53.5%)

>2CM

361(55.5%)

146(46.5%)

1

66(10.2%)

72(22.9%)

2

194(29.9%)

126(40.1%)

3

388(59.9%)

116(36.9%)

1

23(3.7%)

23(7.5%)

2

187(29.8%)

117(38.1%)

3

417(66.5%)

167(54.4%)

11(1.8%)

6(2.0%)

Age (years)

Menopausal status
0.798

Tumour Size
0.008

Tumour Grade
1×10-7

Tubule formation
4×10-4

Pleomorphism
1

1×10-7
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2

196(31.4%)

155(50.5%)

3

418(66.9%)

146(47.6%)

1

157(25.0%)

148(48.2%)

2

117(18.7%)

63(20.5%)

3

353(56.3%)

96(31.3%)

1

398(61.4%)

192(61.1%)

2

195(30.1%)

101(32.2%)

3

55(8.5%)

21(6.7%)

418(64.5%)

202(64.5%)

230(35.5%)

111(35.5%)

147(23.8%)

126(41.7%)

368(59.5%)

144(47.7%)

103(16.7%)

32(10.6%0

Mitosis
1×10-7

Lymph Node Stage
0.558

Lymphovascular
invasion (LVI)
No
Definite

0.993

Nottingham
Prognostic Index
Mild
Moderate
High

1×10-7
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Table 2: The association between Nuclear (N) CHP and different proteins related to
ER and HER2 pathways in the whole patient cohort.
N-CHIP
Negative/low
expression, N (%)

High expression, N (%)

p-value

207(31.7%)

44(14.2%)

1×10-7

447(68.3%)

266(85.8%)

296(47.0%)

97(32.1%)

334(53.0%)

205(67.9%)

272(6.5%)

65(23.7%)

313(53.5%)

209(76.3%)

Hormone receptors
Oestrogen receptor
(ER)
Negative
Positive
Progesterone receptor
(PgR)
Negative

1×10-5

Positive
Androgen receptor
(AR)
Negative

1×10-7

Positive
Triple negative (TN)
status
Non-TN

1×10-5
497(78.1%)

276(89.9%)

139(21.9%)

31(10.1%)

TN
Basal phenotype

5×10-5

Negative

528(82.8%)

285(92.5%)

Positive

110(17.2%)

23(7.5%)

Other ER related proteins
CK7/8

186
Negative

12(1.9%)

3(1.0%)

Positive

621(98.1%)

297(99.0%)

Negative

2(16.2%)

22(7.9%)

Positive

476(83.8%)

258(92.1%)

Negative

63(10.2%)

16(5.4%)

Positive

554(89.8%)

283(94.6%)

Negative

235(38.1%)

104(35.0%)

Positive

382(61.9%)

193(65.0%)

Negative

229(43.8%

144(56.9%)

Positive

294(56.2%)

109(43.1%)

Negative

107(22.3%)

78(34.7%)

Positive

372(77.7%)

147(65.3%)

Negative/low

423(67.9%)

228(77.3%)

Positive

200(32.1%)

67(22.7%)

Negative/low

266(52.3%)

87(34.0%)

High

243(47.7%0

169(66.0%)

0.310

CK18
0.001

CK19
0.014

E-Cadherin
0.368

p-Cadherin
0.001

N-Cadherin
0.001

Tumour suppressor proteins
p53
0.003

BRCA1

Proliferation markers

2×10-6
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KI67-LI
Negative/low

171(33.5%)

138(54.8%)

High

339(66.5%)

114(45.2%)

1×10-7

Apoptosis related
markers
BCL2

219(44.6%)

71(32.7%)

272(55.4%)

146(67.3%)

Negative

482(76.0%)

254(83.6%)

Positive

152(24.0%)

50(16.4%)

Negative

521(82.6%)

273(90.7%)

Positive

110(17.4%)

28(9.3%)

Negative

44(7.5%)

30(10.8%)

Positive

539(92.5%)

248(89.2%)

Negative

65(10.4%)

50(16.4%)

Positive

560(89.6%)

254(83.6%)

Negative/low

0.003

High
HER family proteins
HER1
0.009

HER2
0.001

HER3
0.112

HER4
0.009
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Supplemental Table 1: The list of transcription factors whose DNA-binding activities
were downregulated by CHIP overexpression in ErbB2+ BT474 cells.
ACPBP

E12/E47

L-lll BP

NF-E6/CP1

ADD-1

E2

Lactoferrin-BP

NF-Y

ADR-1

EGR-1

LF-A1

NFkB

ALF-1

EKLF

LSF

p-53

alpha-PAL

ETF

LXRF-1

PAX-2

AML-1

Freac-2

MEF-1

PAX-4

ARP

Freac-4

MRE

PAX-5

ATF

GAG

MT-box

PAX-6

ATF adelta

GBF-1/2/3/HY5

MTF

PBGD BP

ATF-a

H4TF-1

MUSF-1

Pbx1

c-Rel

HFH-1

MyoD

PCF

CACC

HFH-3

MZF1

PEBP-2

CCAAT

HFH-8

NF-1

PPUR

CEBP

HIF-1

NF-1/2

PPUR

CEF-2

HNF-3

NF-4FA

PRDll-BF1

COUP-TF

HNF-4a

NF-Atx

PUR

CTCF

ISGF

NF-E1/YY1

RAR/DR-5

E12

Isl-1

NF-E2

RB
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Supplemental Table 2: The list of transcription factors whose DNA-binding activities
were downregulated by CHIP overexpression in MDA-MB-231 cells.
alpha-PAL

Ets

LF-A2

PTF-1b

ACPBP

Fast-1

LXRE-1

PU1

AF-1

Fra-1/JUN

LyF

PUR

AFP-1

GAG

MAZ

RIPE3a1

AhR/Amt

GATA-3

MDBP

RORE

ALF-1

GBF-1/2/3

MHC W box

RREB

AIC/CBF

GKLF

MEF-2a

Skn

AP-4

HEN-1

Myo D

Sp-1

ARP

HFH-1

MZF1

SPERM-1

ATF

HFH-8/3/LUN

NF-1

SRF

ATF adelta

HFH-11B/11a

NF-4FA

Stat-1/3

CACC

HOX4C

NFAT-1

Tat

CBF

HIF-1

NF-Y

Tax/CREB

CCAC

HiNF-A

OCT

TFE3

Cdx-2

HiNF-B

ORE

TF-LF

CEBP

HNF-1A

P53

TGT-3

c-myb BP

ICSBP

P55

TIF-1

CP-1

Ikoros

PAX-2

TREF-1/2

CSBP

IRF-1/2

PAX-5

URE

CYBP1A1

ISGF

PEBF

WT1

DE-1

KKLF

PEPCK PR

YB-1

E2

Lacto-ferrin BP

PO-B

ZNF174

EKLF

LCR-F1

PPAR

EGR-2

LH2/Lim-1

PPUR
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Supplementary Figure S1. Validate the antibody-based CHIP staining in vitro and in
vivo. (A) Western blotting showed endogenous and exogenous CHIP expression in
breast cancer cell lines. Hsc70 was used as loading control. (B) CHIP IHC staining in
MCF7 CHIP-hi (control shRNA), CHIP-low (CHIP shRNA) and MDA-MB-231cells.
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Supplementary Figure S2. CHIP expression level in breast cancer cell lines. (A) Realtime QPCR analysis shows reduced CHIP mRNA expression in ErbB2+ and triple
negative breast cancer cell lines comparing with ER+ breast cancer cell lines. GAPDH
was used as control. (B) Western blotting showed reduced CHIP protein expression in
ErbB2+ and triple negative breast cancer cell lines comparing with ER+ breast cancer cell
lines. Hsc70 was used as loading control. C) Western blotting showed reduced CHIP
protein expression in most ErbB2+ and triple negative PDX samples. Hsc70 was used as
loading control. (D) Analyses of CHIP, ErbB2, TN status in commercial TMA (BR20837,
from US Biomax)
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Supplementary Figure S3. CHIP-dependent reduction of tumor volume and
metastasis in MDA-MB-231 xenograft model. (A) Representative tumor, liver and lung
organs from MDAMB-231 CHIP-lo (MSCV-puro) and CHIP-hi (MSCV-CHIP) xenograft.
(B) Live and lung metastasis from MDA-MB-231 CHIP-lo (MSCV-puro) and CHIP-hi
(MSCV-CHIP) xenograft were summarized.
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Supplementary Figure S4. MZF1/Cathepsin B expression is regulated by CHIP in
MCF7. (A) Real-time QPCR analysis shows reduced MZF1 mRNA expression in MCF7
CHIP-hi (control shRNA) comparing with CHIP-lo (CHIP shRNA) cells. GAPDH was
used as control. (B) Western blotting showed reduced cathepsin B protein expression in
MCF7 CHIP-hi (control shRNA) comparing with CHIP-lo (CHIP shRNA) cells. Hsc70
was used as loading control.
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Detailed Materials and Methods (Supplementary)
Antibodies and Reagents: Antibodies used for immunoblotting were as follows:
Ubiquitin (mouse monoclonal P4D1; Cat. 3936S, Cell signaling, Denver, PA); ErbB2
(mouse monoclonal; Cat. 554299, BD-Pharmingen, San Jose, CA); MZF1 (mouse
monoclonal; Cat. SAB1402398, Sigma Aldrich, St. Louis, MO); Cathepsin B (rabbit
monoclonal; Cat. Ab125067, Abcam, Cambridge, MA); and HSC70 (B-6 antibody; Cat. sc7298, Santa Cruz Biotechnology, Santa Cruz, CA). Rabbit anti-CHIP antibody used for
blotting has been described (1).A second rabbit antibody (Cat. PA5-29024, Thermo
Scientific, Waltham, MA) was used for IHC staining of CHIP. Secondary antibodies for
immunoblotting included horseradish peroxidase (HRP)-conjugated Protein A or HRPconjugated rabbit anti-mouse antibody (Invitrogen, Carlsbad, CA).
Cell Lysates: Cells were either lysed in RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1% Triton-X-100, 0.05% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 10 mM NaF, and 1 mM sodium orthovanadate) or Triton-X-100 lysis
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Triton-X-100, 1 mM PMSF, 10 mM NaF,
and 1 mM sodium orthovanadate)(2). Lysates were rocked at 4°C for at least 1 hour,
centrifuged at 13,000 rpm for 20 minutes at 4°C and the supernatants assayed for protein
concentration using the BCA assay kit (Thermo Fisher Scientific, Rockford, IL) or the
Bradford assay (Bio-Rad Laboratories, Hercules, CA).
Immunoprecipitation: 1 mg of RIPA lysates and an optimized amount of the indicated
antibody was rocked overnight at 4°C. 200 μl of 10% Protein A Sepharose (GE
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Healthcare, Chalfont St. Giles, UK) beads (washed with RIPA buffer) were added to
each IP sample and rocked at 4°C overnight. The beads were washed five times with
RIPA buffer and bound proteins resolved by SDS-Polyacrylamide (Biorad) Gel
Electrophoresis (PAGE), transferred to Polyvinylidene fluoride (PVDF) membrane (BioRad Laboratories, Hercules, CA) and subjected to Western Blotting(1).
RNA extraction and real-time PCR: The total RNA was extracted using TRIzol reagent
(Invitrogen), reverse transcribed using Quantitative real-time PCR kit (cat. 204141,
Qiagen, Germantown, MD) was performed using the following primers: (a) MZF1
forward primer 5’-CGTAGAGAAGTGAGGAAA-3’ and reverse primer 5’ATGATCAGGTCATACTCC-3’; (b) CTSB forward primer 5’AACCACAGGCTGGGATGTAG-3’ and reverse primer 5’CACTGACTGGGGTGACAATG-3’; (c) CTSL forward primer 5’GATGGAGGAGAGCAGTGTGG-3’and reverse primer 5’GCACTAAAAGCCCAACAAGAAC-3’; (d) GAPDH forward primer 5’CCACTCCTCCACCTTTGAC-3’ and reverse primer 5’-ACCCTGTTGCTGTAGCCA-3’.
Transfection Reagents and Plasmids: XtremeGENE 9 transfection reagent was from
Roche Applied Science (Indianapolis, IN). A pMSCV expression construct encoding the
Myc- epitope-tagged full-length CHIP protein (amino acids 1–303) was generated as
described preciously(3).
Cumulative proliferation assay: Cells were seeded in 6-well plates at 5,000 cells per
well, counted after seven-day culture and re-plated in fresh 6-well plates at the original

200
plating density for a total of five serial passages. The cumulative cell numbers were
calculated based on the fractions of each harvest used for replating and plotted as a
function of the overall time in culture.
Anchorage-independent growth assay: 2,500 cells were seeded in 0.35% soft agar on top
of 0.6% soft agar layer in 6-well plates. After two weeks, cells were stained with crystal
violet and imaged under a phase contrast microscope. The colonies from the whole wells
were enumerated using Image J (NIH, MD). All experiments were done in triplicates,
and repeated three times.
Transwell migration and invasion assays: The cells were seeded in the top chamber of
transwell chambers with 8 μm pore size nitrocellulose filters (Corning) in serum-free
medium. Medium containing 10% FBS served as a chemoattractant in the lower
chamber. For the invasion assay, the membranes were coated with 1:2 diluted Matrigel
(BD Biosciences) before seeding the cells. After 24 h, the cells on the upper side of the
membrane were removed by scraping with cotton swabs, while those on the lower side
were fixed with methanol, stained with crystal violet and cells were counted.
Experiments were run in triplicates and repeated thrice. For invasion assay in Figure 7,
cells were seeded in top chambers of 96-well invasion chambers coated with Matrigel
(CytoSelect™ 96-well Cell Invasion Assay Kit; Cat. CBA112, Cell Biolabs, INC.) followed
by analyses as in migration assays.
Extracellular matrix degradation assay: This assay was carried out using QCM™
Gelatin Invadopodia kit (Cat. ECM670, EMD Millipore, Billerica, MA) according to the
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manufacturer’s protocol. FITC-labeled gelatin was coated onto glass chamber slides and
crosslinked with 0.5% glutaraldehyde in PBS for 30 minutes. Slides were then washed
three times each with PBS and 50 mM glycine in PBS. Cells were cultured for various
time points to allow ECM degradation, seen as focal loss of fluorescent signal (“holes”)
in the labeled gelatin layer. Experiments were run in replicates and repeated thrice. Six
fields per chamber were imaged and the fluorescence intensity was further analyzed
using Image J (NIH).
In vivo xenograft experiment: 10 million cells mixed with 0.2 ml Matrigel (BD
Biosciences) were implanted in the mammary fat pad of 4-6 week old non-pregnant
female NSG mice (The Jackson Laboratory). Three days prior to cell implantation, the
mice were primed with s/c estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research
of America, Sarasota, FL). Tumor growth was monitored weekly for 10 weeks. Tumor
dimensions were measured with Vernier calipers and tumor volume calculated as length
x width x depth/2. Mice were euthanized when control tumors reached 2 cm3 in volume
or showed signs of ill health, as per institutional IACUC guidelines. At the end of the
experiment the tumor, as well as liver and lung, are resected, and formalin-fixed and
paraffin-embedded for further analyses.
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